Dictionary domainTrack D
Clinical research and clinical trials
Clinical trial protocols, IND/IDE filings, case report forms, and HIPAA research-disclosure rules.
Terms in this domain
172 terms
TGA CTN and CTA (formerly CTX) Schemes
The CTN (Clinical Trial Notification) and CTA (Clinical Trial Approval, formerly called CTX -- Clinical Trial Exemption) schemes are the two regulatory pathways Australia's Therapeutic Goods Administration (TGA) uses to permit the lawful supply of an 'unapproved' therapeutic good -- one not yet entered on the Australian Register of Therapeutic Goods (ARTG) -- for use in a clinical trial. A trial is a CTN trial if the sponsor self-assesses the product and trial as suitable to proceed on notification alone: the sponsor lodges a CTN with the TGA (via the TGA Business Services online CTN form) after the trial protocol has HREC (Human Research Ethics Committee) approval, pays the CTN fee, and the trial may then start -- the TGA does not review the scientific data before the trial begins. A trial is a CTA trial if the sponsor instead applies for the TGA's formal evaluation and approval of the unapproved good before the trial can start; the TGA reviews the supporting data (quality, safety, and available efficacy information) and must approve the application before recruitment begins. Both schemes sit alongside, not instead of, HREC ethical review and (for CTN trials) the relevant institution's own governance authorisation -- TGA approval or notification concerns lawful supply of the unapproved product, not the ethics of the study design.
TCET (Transitional Coverage for Emerging Technologies)
TCET (Transitional Coverage for Emerging Technologies) is a CMS coverage pathway, finalized August 2024 (final procedural notice CMS-3421-FN, effective August 12, 2024), that expedites Medicare national coverage for a limited set of FDA-designated Breakthrough Devices by running the device through CMS's existing National Coverage Determination (NCD) and Coverage with Evidence Development (CED) machinery on an accelerated, pre-planned timeline rather than creating a new coverage authority. A device becomes TCET-eligible only if it holds FDA Breakthrough Device designation, has received FDA market authorization, falls within an existing Medicare benefit category, and is not already the subject of an NCD; CMS finalized an exclusion for digital-only technologies and capped the pathway at five new candidates accepted per year, reviewed on a quarterly cycle. A manufacturer engages CMS well before authorization: a non-binding Letter of Intent roughly 18-24 months out, formal self-nomination roughly 12 months out, a CMS-contractor-generated evidence preview identifying gaps in the existing clinical evidence, and a manufacturer-authored Evidence Development Plan (EDP) mapping how those gaps will be closed. If accepted, CMS pursues an NCD conditioned on CED, giving the device national Medicare coverage for several years -- potentially up to roughly five -- while the manufacturer collects the additional outcomes data the evidence preview identified as missing.
PMDA Clinical Trial Notification (CTN)
A Clinical Trial Notification (CTN, chiken todokede) is the regulatory filing a sponsor must submit to Japan's Ministry of Health, Labour and Welfare (MHLW) -- reviewed on MHLW's behalf by the Pharmaceuticals and Medical Devices Agency (PMDA) -- before initiating a clinical trial of an unapproved drug, or a new indication/dosage of an approved drug, in Japan. It is Japan's functional counterpart to a U.S. FDA Investigational New Drug (IND) application, but operates as a notification-and-review-window system rather than an affirmative approval: for an initial CTN, PMDA has a 30-day review period after receipt in which it can raise questions or object; if PMDA raises no objection within that window, the sponsor may proceed to start the trial. A submission counts as a CTN when it is filed under Japan's PMD Act (Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices) and includes the trial protocol, investigational product information, and details of the investigators and institutions where the trial will be conducted.
REMS (Risk Evaluation and Mitigation Strategy)
A REMS is a required FDA drug safety program, authorized under Section 505-1 of the Food, Drug, and Cosmetic Act (added by the 2007 FDAAA), imposed on a drug or biologic when FDA determines its serious risks require controls beyond standard professional labeling. It can combine a Medication Guide, a prescriber/provider communication plan, and Elements to Assure Safe Use (ETASU) such as prescriber or pharmacy certification, restricted dispensing settings, mandatory patient monitoring, or registry enrollment -- with an implementation system required whenever ETASU is used.
GA4GH (Global Alliance for Genomics and Health)
An international not-for-profit alliance, founded in 2013, that develops and maintains technical interoperability specifications and policy frameworks (such as the Data Use Ontology, GA4GH Passport, Beacon, htsget, Crypt4GH, and Phenopackets) enabling genomic and health-related data to be shared responsibly across research and clinical institutions worldwide; GA4GH does not host data itself but defines the standards that repositories, biobanks, and national genomic initiatives implement to interoperate.
Advarra IRB
<p><strong>Advarra</strong> is a commercial (independent) Institutional Review Board (IRB) provider based in Columbia, Maryland, formed in 2017 through the merger of Chesapeake IRB and Schulman IRB and expanded in 2019 through the acquisition of Quorum Review IRB. It is one of the largest commercial IRBs operating in the United States, reviewing human-subjects research on a fee-for-service basis for pharmaceutical, biotech, medical-device, and academic sponsors, and is frequently designated as the <a href='/dictionary/term/central-irb-single-irb-sirb'>central IRB / single IRB of record (sIRB)</a> for multi-site clinical trials. Advarra is registered with the Office for Human Research Protections (OHRP) under 45 CFR 46 and with FDA under 21 CFR Part 56, and holds full accreditation from <a href='/dictionary/term/aahrpp-association-for-the-accreditation-of-human-research-protection-programs'>AAHRPP</a>. Sites and sponsors submit and track studies through Advarra's electronic platform, the Center for IRB Intelligence (CIRBI).</p>
Network Meta-Analysis (NMA)
Network meta-analysis (NMA) is a statistical technique that estimates the comparative effectiveness of three or more interventions within a single unified model by combining two kinds of evidence: direct evidence, from trials that compared two of the interventions head-to-head, and indirect evidence, inferred through one or more common comparators (such as a shared placebo or standard-of-care arm) that connect trials which never compared those two interventions directly. A body of evidence qualifies as an NMA, rather than a standard pairwise meta-analysis, when it (1) includes three or more interventions across the included trials, (2) links those trials into a connected network via shared comparators, and (3) produces relative-effect estimates for treatment pairs even when no trial tested that pair directly. NMA rests on an assumption called transitivity — that trials contributing indirect evidence are similar enough in patient population, setting, and other effect modifiers that comparisons through a common comparator are valid — and its statistical counterpart, consistency, which checks that direct and indirect estimates for the same pair of interventions agree.
Investigator’s Brochure (IB)
The Investigator's Brochure (IB) is the ICH E6(R2)-required compilation of physical, chemical, pharmaceutical, nonclinical, and available clinical data on an investigational product, supplied by the sponsor to investigators and the IRB/IEC before a trial begins and kept current through an ongoing review-and-update obligation for as long as the product remains investigational, so investigators can make an informed risk-benefit assessment and comply with protocol-specified dosing and safety monitoring.
Plain Language Summary (PLS)
<p>A <strong>plain language summary (PLS)</strong> is a short, jargon-free account of a clinical trial's design and results, written so that a layperson — typically framed as a trial participant or member of the public — can understand what the study tested, what it found, and what that means, without needing scientific or medical training. In EU-regulated clinical trials it is a defined regulatory deliverable, not an optional courtesy: under <a href='https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32014R0536' target='_blank' rel='noopener'>Regulation (EU) No 536/2014</a> (the EU Clinical Trials Regulation, CTR), sponsors of trials authorised under the Regulation must submit a lay summary of the trial's results to the Clinical Trials Information System (CTIS) alongside the technical results summary, generally within 12 months of the trial's global end date. That deadline extends to up to 30 months for certain non-therapeutic Phase 1 trials, and shortens to 6 months for paediatric trials. Lay summaries must generally be provided in the official language(s) of the EU/EEA member state(s) where the trial was conducted, not only in English.</p><p>An instance of a PLS is a written summary that (a) covers the trial's purpose, participant population, methods, and results including any relevant safety information, (b) is written for a non-specialist reading level (commonly targeted around a 12-14 year-old reading age in EMA/national guidance), and (c) is submitted as a distinct, identifiable document alongside — not merged into — the technical/scientific summary of results. A document that simply restates the scientific abstract in shorter form, or that omits the trial's actual findings in favour of only describing its design, does not meet the operational bar even if labelled a lay summary.</p>
PICOTS Criteria
A research question is PICOTS-structured when it explicitly specifies all six elements — Population, Intervention, Comparator, Outcome, Timing, and Setting — rather than only the four PICO elements, typically to derive study-eligibility criteria for a systematic review, evidence synthesis, or health-technology assessment protocol.
Patient Consent for Case Report Publication
The written authorization a patient (or parent/guardian/legally authorized representative) gives before a clinical case report describing their presentation, treatment, images, or outcome is submitted to a journal -- required whenever the report contains identifiable information, per ICMJE's patient-privacy recommendations and CARE Guidelines checklist item 13, independent of any separate IRB determination about the underlying case.
Retrospective Study
A retrospective study is an observational research design in which investigators identify subjects, exposures, and outcomes that have already occurred and reconstruct the exposure-outcome relationship from data recorded before the study began -- most often clinical records, administrative/claims data, registries, or prior test results -- rather than measuring events as they unfold going forward. What makes a study retrospective is not its statistical method but the timing relationship between the start of the study and the events under analysis: if the outcome had already happened before subjects were identified and data collection began, the study is retrospective, regardless of whether it is framed as a cohort, case-control, or case-series design. Because the data were typically generated for clinical care, billing, or another purpose unrelated to the study's hypothesis, retrospective studies trade weaker control over data quality and measurement consistency for speed, lower cost, and the ability to study rare outcomes or long latency periods that a forward-looking design could not practically capture.
Participant Health Literacy
Participant health literacy is the degree to which a prospective or enrolled research participant can find, understand, and act on the information needed to make a voluntary decision about joining a study and to follow study procedures once enrolled. In practice, a research team is designing for participant health literacy whenever it (1) writes consent forms, recruitment materials, and result-summary/plain-language-summary documents at a reading level and format the target population can actually process (commonly benchmarked to roughly a 6th-8th grade level, though neither the Common Rule nor FDA regulations set a numeric threshold -- both simply require information 'understandable to the subject'), and (2) actively checks comprehension rather than assuming it, most often via the teach-back method: asking the participant to restate key study facts (purpose, main procedures, risks, voluntariness, right to withdraw) in their own words before consent is finalized. A document or process only counts as addressing health literacy if both elements -- accessible language AND a comprehension check -- are present; a well-simplified form that nobody ever asks the participant to explain back is a partial, not complete, application of the concept.
ICH E6(R2) Section 5 Sponsor Obligations
A duty ICH E6(R2) Section 5 (subsections 5.0 through 5.23) assigns by default to the trial sponsor -- spanning quality management, quality assurance/control, CRO oversight, trial management and recordkeeping, investigator selection, subject/investigator compensation, investigational-product supply, safety reporting and monitoring, audit, noncompliance handling, trial termination/suspension, and multicenter-trial coordination -- that the sponsor retains unless specifically transferred in writing to a CRO under Section 5.2.
Human Fetal Tissue Research (NIH Policy Framework)
Human fetal tissue (HFT) research is research using tissue or cells obtained from a deceased human embryo or fetus, most often following a pregnancy loss. Where federal funding is involved and the tissue was obtained from an induced (elective) abortion, HFT research is governed by a distinct statutory and policy layer on top of the general Common Rule: the NIH Revitalization Act of 1993 (42 U.S.C. §§289g-1, 289g-2), which sets informed-consent and donation conditions and establishes a Human Fetal Tissue Research Ethics Advisory Board (EAB) mechanism for reviewing funding decisions on ethical grounds, plus successive HHS/NIH policy notices that have repeatedly changed whether and how such research may be federally funded.
NREC (National Office for Research Ethics Committees, Ireland)
The NREC (National Office for Research Ethics Committees) is the statutory Irish body, hosted by the Health Research Board (HRB) since 2020, that establishes and administers Ireland's National Research Ethics Committees for legally regulated research: clinical trials of investigational medicinal products (NREC-CT) and clinical investigations of medical devices (NREC-MD), plus committees stood up for specific national needs such as the National Irish COVID-19 Biobank (NICB-REC) and COVID-19 research (NREC COVID-19). A study falls under NREC review, rather than a local HSE, hospital, or university Research Ethics Committee, when it is a Regulated Clinical Trial under the EU Clinical Trials Regulation (536/2014) or a regulated medical-device clinical investigation, in which case a single national ethics opinion from the relevant NREC is required, issued in a coordinated procedure alongside the scientific/regulatory assessment carried out by the Health Products Regulatory Authority (HPRA). Outside that regulated scope, most observational studies, most academic health and social-care research, and research within the HSE and HSE-funded hospitals, ethical review remains the responsibility of local HSE and Hospital Research Ethics Committees, not the NREC.
Waiver of Informed Consent (45 CFR 46.116(f))
A waiver of informed consent under 45 CFR 46.116(f) is an IRB determination that a study may enroll subjects, or use their identifiable private information or identifiable biospecimens, without obtaining informed consent at all -- distinct from merely waiving the signed-form requirement under 46.117(c). An IRB (or, for research eligible for expedited review, an IRB chair or designated reviewer) may approve a full waiver or alteration of consent only after finding, and documenting in the study record, that all five criteria in 46.116(f)(3) are met: (i) the research involves no more than minimal risk to the subjects; (ii) the research could not practicably be carried out without the waiver or alteration; (iii) if the research uses identifiable private information or identifiable biospecimens, it could not practicably be carried out without using that information or those biospecimens in identifiable form; (iv) the waiver or alteration will not adversely affect the rights and welfare of the subjects; and (v) whenever appropriate, subjects or their legally authorized representatives will be provided with additional pertinent information after participation. This mechanism is the standard route for retrospective chart-review and secondary-database research, where re-contacting every prior patient to obtain prospective consent is often not feasible and would itself undermine the value or completeness of the dataset.
ICH E2A (Clinical Safety Data Management: Definitions and Standards for Expedited Reporting)
ICH E2A is the ICH tripartite guideline (Step 4, 1994; adopted by FDA, EMA, and Japan) that defines Adverse Event, Adverse Reaction, Serious, and Unexpected, cascades those into the SUSAR (Suspected Unexpected Serious Adverse Reaction) category, and sets the expedited safety-reporting clock -- 7 calendar days for fatal/life-threatening SUSARs, 15 calendar days for all other SUSARs, measured from sponsor awareness. It is the regulatory-standard-level source that IND Safety Reports, Safety Letters, and national expedited-reporting rules (21 CFR 312.32 in the US; EU Regulation (EU) No 536/2014) all implement.
Translated Informed Consent Materials
Consent materials count as compliant "translated informed consent" when they make the required disclosure elements of 45 CFR 46.116 (and, for FDA-regulated research, 21 CFR 50.25) understandable to a prospective participant who does not read or speak English proficiently — satisfied through one of two IRB-approved pathways: (1) a fully translated long-form consent document, reviewed and approved by the IRB before use, or (2) the short-form written consent process under 45 CFR 46.117(b)(2) / 21 CFR 50.27(b)(2), in which a brief document in the participant's language states that the required elements were presented orally, backed by a bilingual witness and the English-language summary the person obtaining consent signs. Neither pathway is optional paperwork — both require prospective IRB approval, and neither can be improvised at the bedside or in the field without one.
Medicare Clinical Trial Policy (NCD 310.1)
The Medicare Clinical Trial Policy is the national coverage framework, codified as National Coverage Determination (NCD) 310.1 ("Routine Costs in Clinical Trials"), under which Medicare pays the routine patient-care costs of a beneficiary enrolled in a qualifying clinical trial, plus reasonable and necessary costs of treating complications from participation. A trial only qualifies if it meets three threshold criteria (the studied intervention falls within a Medicare benefit category, the trial has therapeutic intent, and trials of a therapeutic intervention enroll patients with a diagnosed disease) and satisfies at least one deeming criterion: funding or endorsement by NIH, CDC, AHRQ, CMS, DOD, or VA (or by a cooperative group/center they support); conduct under an FDA Investigational New Drug (IND) application; or exemption from IND requirements as a drug trial under 21 CFR 312.2(b)(1). A trial that meets none of these is not automatically excluded, but its sponsor must instead complete CMS's qualifying-trial checklist demonstrating the trial's scientific validity and integrity. Separately, since Change Request 5790 (Transmittal 310, effective 2008), Medicare claims for routine costs under a qualifying trial must report the trial's ClinicalTrials.gov identifier (the NCT number) alongside condition code 30 -- so registration in the National Library of Medicine's public registry functions, in practice, as a billing prerequisite: a claim without a valid NCT number is at risk of denial even if the trial itself otherwise qualifies.
Pilot Study
A small-scale study that runs a scaled-down but methodologically faithful version of a planned future study’s actual protocol — same recruitment approach, same intervention delivery, same outcome measures and data-collection procedures — in order to test whether the full-scale study is workable, refine its methods and instruments, and generate preliminary parameter estimates (recruitment rate, adherence, rough effect size or outcome variance) before committing to the definitive study. A pilot study is one specific subtype of feasibility study — the one that tests feasibility by actually running the intended methods, rather than assessing feasibility through other means (surveys, record review, capacity audits). It is not designed to formally test whether an intervention works, and it is a distinct concept from a Phase I clinical trial, which is a defined stage in the drug-development regulatory pathway rather than a general research-methodology device.
CARE Case Report Guidelines
The CARE (CAse REport) Guidelines are a 13-item reporting checklist, developed by an international consensus group and published in 2013, that specifies what a clinical case report must include -- patient information, timeline, diagnostic assessment, intervention, and outcome -- for it to be complete, transparent, and usable by other clinicians and reviewers.
Statistical Analysis Plan (SAP)
A Statistical Analysis Plan (SAP) is the pre-specified document that translates a clinical trial protocol's objectives and endpoints into the exact statistical methodology that will be used to analyze the trial's data — which populations are analyzed (e.g. intent-to-treat/full analysis set vs. per-protocol set), which statistical tests and models are applied to each endpoint, how missing data and multiplicity are handled, and what any interim or subgroup analyses will consist of. A document only functions as a genuine SAP if it is finalized and version-locked before database lock and unblinding — that is, before anyone with access to outcome data can see how the results turn out. A statistical methods section written or substantively revised after the analysts already know (or could infer) the results is not a valid SAP in the ICH E9 sense, regardless of what it is called, because it no longer prevents the analytic flexibility (selective reporting, post-hoc subgroup mining, outcome-switching) that pre-specification exists to close off.
Comparator Sourcing
Comparator sourcing is the procurement of an already-approved active comparator drug for use as a trial's control-arm treatment (instead of, or alongside, placebo), plus the blinding, chain-of-custody/authenticity verification, and regulatory handling (GMP/GDP, IMP labeling, import licensing) required once that product enters the study.
SUSAR (Suspected Unexpected Serious Adverse Reaction)
A SUSAR (Suspected Unexpected Serious Adverse Reaction) is an adverse event in a clinical trial that meets three conditions at the same time: it is <strong>serious</strong> under the <a href="https://ich.org/page/efficacy-guidelines" target="_blank" rel="noopener noreferrer">ICH E2A</a> seriousness criteria (death, life-threatening, hospitalization/prolongation, persistent or significant disability, congenital anomaly, or another medically important event), the investigator or sponsor judges there is a reasonable possibility it was <strong>caused by</strong> the investigational product (a suspected causal relationship, not confirmed causation), and it is <strong>unexpected</strong> — not listed or not consistent in nature, severity, or specificity with the reference safety information in the current Investigator's Brochure (or approved labeling for an active comparator). All three elements must hold; an event failing any one of them is not a SUSAR. Identifying a SUSAR is what triggers expedited, individual-case safety reporting to regulators, separate from and faster than routine trial adverse-event reporting.
Clinical Trial Transparency
Clinical trial transparency is the umbrella principle that every clinical trial's existence, design, and outcome should be made public regardless of what the results show. A given practice counts as advancing clinical trial transparency when it does at least one of three things: (1) makes a trial discoverable before it enrolls participants (prospective registration in a WHO-recognized registry such as ClinicalTrials.gov, ISRCTN, or EU CTIS), (2) makes that trial's summary results discoverable after it ends, including when results are negative, null, or unfavorable to the sponsor (results reporting, most concretely enforced in the US through FDAAA 801 and its implementing regulation, 42 CFR Part 11), or (3) makes the underlying protocol, statistical analysis plan, or individual participant-level data available for independent scrutiny (clinical data sharing). It is a movement and a set of overlapping obligations and voluntary commitments, not a single regulation -- a trial can satisfy one pillar (say, registration) while failing another (results reporting), which is precisely the gap transparency advocacy has spent over a decade trying to close.
SMART IRB Reliance Agreement
The SMART IRB Reliance Agreement is a master common reliance agreement -- a single legal contract that participating US institutions each sign once with the SMART IRB platform -- that pre-establishes the terms under which any two (or more) participating institutions may rely on one another's IRB review for a given multi-site human subjects study. Once an institution has executed the master agreement, individual studies between it and any other participating institution invoke that existing agreement through an online reliance-determination process, rather than each study requiring its own bespoke IRB Authorization Agreement negotiated and signed from scratch.
IRB Reportable Events
An IRB reportable event is any occurrence, finding, or piece of new information arising during an already-approved, ongoing human subjects study that federal regulation or an institution's Human Research Protection Program (HRPP) policy requires the study team to report to the IRB outside the routine continuing-review cycle. This is distinct from the initial IRB application/approval process (see IRB/REC Approval Process) and from a planned protocol amendment submitted for prior approval before a change is implemented -- a reportable event concerns something that has already happened during the conduct of the study. The umbrella category typically includes: unanticipated problems involving risks to subjects or others (UPIRSOs), protocol deviations (especially those affecting subject safety, rights, or data integrity), adverse events and serious adverse events, subject complaints, breaches of confidentiality, and non-compliance with the approved protocol or applicable regulations.
Expansion Cohort
An expansion cohort is a group of participants enrolled at a dose already selected during a Phase 1 trial's dose-escalation stage -- typically the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) -- to further characterize that dose's safety and generate preliminary evidence of clinical activity. A trial design qualifies as using expansion cohorts when it runs dose escalation and one or more fixed-dose expansion cohorts under a single protocol, most commonly in first-in-human oncology trials; multiple expansion cohorts run in parallel (by tumor type or biomarker) at the same dose are described as a multiple expansion cohort (MEC) design.
Simplified Consent Arrangements for Adults Lacking Capacity (UK Clinical Trials)
In UK clinical trials of investigational medicinal products (CTIMPs), "simplified consent arrangements for adults lacking capacity" refers to the alternative consent pathway set out in Schedule 1, Part 5 of the Medicines for Human Use (Clinical Trials) Regulations 2004 (as amended) that applies when a prospective or enrolled participant cannot give informed consent for themselves. Rather than the participant's own signature, the regulations require consent from a <em>legal representative</em> acting on the adult's behalf: first a <strong>personal legal representative</strong> (someone not connected with the conduct of the trial who is suitable by virtue of their relationship with the adult, and who is available and willing to act), or, if no personal legal representative is available, a <strong>professional legal representative</strong> (typically the doctor primarily responsible for the adult's medical treatment, provided they are independent of the trial, or a person nominated by the relevant health service body). A further, narrower simplification applies to genuinely urgent research: where the trial's protocol has been specifically approved by a recognised Research Ethics Committee for enrolment in urgent situations, an incapacitated adult may be entered into the trial without any prior consultation of a legal representative if urgent action is needed to give the investigational medicinal product and it is not reasonably practicable to consult one first — on condition that consent (or continued participation) is then sought from a legal representative, or the adult themselves if capacity is regained, as soon as reasonably possible afterwards. CTIMPs are explicitly excluded from the separate Mental Capacity Act 2005 research provisions (MCA s.30) precisely because this dedicated Schedule 1 regime governs them instead; other (non-CTIMP) research involving adults who lack capacity in England and Wales instead follows the MCA 2005 consultee-based framework. This term covers the CTIMP-specific, legal-representative pathway only.
MHRA GCP Inspection
An MHRA GCP inspection is an on-site or remote audit conducted by the UK Medicines and Healthcare products Regulatory Agency's GCP Inspectorate to assess whether a clinical trial sponsor, contract research organisation (CRO), or investigator site is conducting research in compliance with the UK Clinical Trials Regulations and the principles of Good Clinical Practice (GCP) set out in ICH E6. Inspections are the mechanism by which the MHRA verifies that trial data submitted in support of a marketing authorisation can be trusted and that participants' rights, safety, and wellbeing were protected during the conduct of the trial.
ICH E9 (Statistical Principles for Clinical Trials)
ICH E9, "Statistical Principles for Clinical Trials," is the International Council for Harmonisation guideline (finalized 1998) that sets out the core statistical methodology expected of a confirmatory clinical trial submitted to a regulatory authority. A trial's design and statistical analysis plan (SAP) are ICH E9-consistent when they are pre-specified before unblinding and address, at minimum: the trial's overall design and hypothesis structure (superiority, non-inferiority, or equivalence, each with its own margin and testing logic); the randomization and blinding scheme; the sample-size/power justification; the choice of analysis populations, most centrally the Full Analysis Set (FAS, an operationalization of the intention-to-treat principle) and the Per-Protocol Set (PPS); the handling of missing data; and the control of Type I error across multiple endpoints, interim looks, or comparisons (multiplicity). ICH E9 was substantially extended, not replaced, by its 2019 addendum ICH E9(R1), which introduced the estimand framework to address a gap the original guideline left largely implicit: how a trial's statistical objective should be translated into a precisely defined treatment-effect question before an analysis method is chosen to answer it.
FDA Biomarker Qualification Program
A biomarker is qualified under FDA's Biomarker Qualification Program (BQP) when FDA has completed formal review under Section 507 of the FD&C Act (added by the 21st Century Cures Act, 2016) and determined the biomarker is reliable for a specific, defined context of use (COU) -- meaning any sponsor may rely on it for that COU across multiple, unrelated drug development programs without independently re-justifying its validity to FDA each time. This is distinct from a biomarker FDA accepts, or does not object to, only within one sponsor's single IND or trial -- that acceptance is program-specific, not portable, and must be independently re-justified for any other use.
ICH M4 (Common Technical Document / CTD)
ICH M4 is the International Council for Harmonisation (ICH) multidisciplinary guideline that defines the Common Technical Document (CTD): a standardized, five-module dossier structure for organizing the quality, safety, and efficacy data submitted to regulatory authorities when registering a pharmaceutical for human use. A submission is CTD-compliant when its content is organized into Module 1 (region-specific administrative information), Module 2 (CTD summaries), Module 3 (quality/CMC data), Module 4 (nonclinical study reports), and Module 5 (clinical study reports), with Modules 2-5 following the same harmonized content and ordering regardless of which ICH regulatory authority receives the application. M4 is a family of related documents rather than a single guideline: the overarching M4 organizational guideline is supplemented by M4Q (Quality), M4S (Safety/nonclinical), and M4E (Efficacy/clinical), each specifying the detailed content and ordering for its respective module.
NIH Inclusion Policies (Women, Minorities, and Across the Lifespan)
A study satisfies NIH inclusion requirements when its application describes the planned participant population by sex/gender, race/ethnicity, and age range appropriate to the science; provides a compelling rationale for any exclusion of women, a minority group, or an age range rather than defaulting to exclusion; and, for Phase III trials, includes a valid analysis plan for whether effects differ by sex/gender and race/ethnicity. This combines two distinct NIH policies: the statutory Inclusion of Women and Minorities policy (sex/gender and race/ethnicity, in force since the 1993 NIH Revitalization Act) and the Inclusion Across the Lifespan policy (age, including children and older adults, in force since January 25, 2019 under NOT-OD-18-116).
45 CFR 46 Subpart C (Additional Protections for Prisoners in Research)
The section of the Common Rule (45 CFR 46, §§46.301-46.306) that governs HHS-conducted or HHS-funded biomedical or behavioral research involving prisoners as subjects. A protocol falls under Subpart C whenever a subject meets the §46.303 definition of "prisoner" — involuntary confinement or detention in a penal institution, including pretrial detainees and individuals in alternative-to-incarceration facilities. The reviewing IRB must satisfy the §46.304 composition requirements (a non-prison-affiliated majority plus at least one prisoner or prisoner representative), make the additional findings required by §46.305, and may approve the research only if it fits one of the four categories permitted under §46.306.
Clinical Data Registry
A clinical data registry is an organized system that collects standardized, defined-variable clinical and outcomes data on patients sharing a common condition, procedure, exposure, or device, on an ongoing rather than fixed-enrollment basis. What makes a data-collection effort a registry, rather than an ordinary clinical database or a clinical trial, is a combination of: (1) a defined denominator population identified by disease, procedure, or exposure, not by eligibility for a specific tested intervention; (2) a standardized, pre-specified data dictionary applied consistently across contributing sites, enabling pooled and benchmarked analysis; and (3) an ongoing or periodically re-opened collection window rather than a protocol-bound enrollment period. Registries are most often sponsored by a medical specialty society, a health system, a public health agency, or a manufacturer under a post-market surveillance obligation, and their stated purposes typically include quality improvement and benchmarking, observational research, public health surveillance, and, in a growing but still bounded set of cases, support for regulatory decision-making.
45 CFR 46 Subpart A (Basic HHS Policy for Protection of Human Research Subjects)
The foundational section of the Common Rule (45 CFR 46, §§46.101-46.124) that establishes the general framework HHS-conducted or HHS-funded human-subjects research must satisfy: which activities and institutions it covers (§46.101), the core definitions of "human subject" and "research" (§46.102), the institutional assurance and IRB registration structure (§46.103), the eight categories of exempt research (§46.104), IRB membership and operating requirements (§46.107-46.115), and the general standards for informed consent (§46.116-46.117). Subpart A is the baseline every other subpart (B, C, D) layers additional, population-specific protections on top of — in ordinary usage, "the Common Rule" and "Subpart A" refer to essentially the same body of regulatory text.
HIPAA and Retrospective Research
A retrospective study (most commonly a retrospective chart review) uses protected health information (PHI) that was already recorded in the medical record before the research began, rather than PHI generated by a prospective study protocol. Because the individuals were treated in the past and often cannot practicably be found and asked for HIPAA authorization, retrospective research typically proceeds under 45 CFR 164.512(i)(1)(i): an IRB or Privacy Board grants a full or partial waiver of authorization after documenting, per 164.512(i)(2), that (1) the use/disclosure involves no more than minimal privacy risk, based on an adequate plan to protect identifiers, an adequate plan to destroy identifiers at the earliest opportunity absent a health or research justification to retain them, and written assurances against reuse or redisclosure; (2) the research could not practicably be conducted without the waiver; and (3) the research could not practicably be conducted without access to the PHI. A study only qualifies as retrospective-research-under-waiver if it is genuinely using pre-existing records for a defined research protocol -- not if it is a 'review preparatory to research' (164.512(i)(1)(ii), used only to help design a study or assess feasibility, with no PHI leaving the covered entity) or decedent-only research (164.512(i)(1)(iii)), which are the Rule's two other, separate no-authorization pathways.
Exception from Informed Consent (EFIC) for Emergency Research
EFIC (Exception from Informed Consent) is the regulatory pathway under 21 CFR 50.24 that permits FDA-regulated clinical investigations of a drug, biologic, or device to enroll subjects in a life-threatening emergency without prospective informed consent from the subject or a legally authorized representative (LAR). A study qualifies as EFIC only when all of the following are true: (1) subjects are in a life-threatening situation for which available treatments are unproven or unsatisfactory; (2) obtaining informed consent is not feasible because the condition requires intervention before consent from the subject or LAR can reasonably be obtained; (3) participation holds the prospect of direct benefit to the subject; (4) the research could not practicably be carried out without the waiver; and (5) additional protections are in place, most notably community consultation and public disclosure conducted before the study begins, and an independent data monitoring committee. IRB approval of the full protocol, including the community consultation and disclosure plan, is required before enrollment can start under the exception.
45 CFR 46 Subpart B (Additional Protections for Pregnant Women, Human Fetuses, and Neonates)
The section of the Common Rule (45 CFR 46, §§46.201-46.207) that governs HHS-conducted or HHS-funded research in which the subjects are pregnant women, human fetuses, or neonates. A protocol falls under Subpart B whenever a subject meets the §46.202 definition of pregnant woman, fetus, or neonate; the IRB must then apply the specific risk/benefit and consent conditions for the applicable subject category (§46.204 pregnant women/fetuses, §46.205 neonates, §46.206 material obtained after delivery) before approving the research, with §46.207 available as a narrow, HHS-Secretary-level pathway for research that does not otherwise qualify.
Case Report IRB Exemption
A case report is generally treated as exempt from IRB (Common Rule) jurisdiction when it describes routine clinical care of one patient (or a small, non-systematically-assembled number), written up retrospectively with no predefined data-collection protocol and no intent to test a hypothesis or produce a generalizable conclusion — i.e., it fails the 45 CFR 46.102(l) definition of 'research' even though the patient meets the 46.102(e) 'human subject' definition. The determination is made by the IRB or a delegated research-compliance office, not by the author; institutional thresholds and required documentation vary, and HIPAA authorization/waiver plus patient consent for publication remain separately required regardless of Common Rule status.
Close-Out Visit (COV)
A Close-Out Visit (COV) is the final monitoring visit a sponsor or its Clinical Research Associate (CRA) conducts at a clinical trial site after the site has finished its participation in a study -- either because the site reached its last participant's last visit (LPLV) or because the trial or the site's participation was terminated early. A monitoring visit qualifies as a COV, rather than a routine Interim Monitoring Visit (IMV), only when it is the final visit for that site and confirms four things together: all outstanding data queries are resolved (or an agreed plan exists for any that cannot be), all required essential documents are complete and filed in the Trial Master File (TMF), investigational product (IP) has been reconciled and, per protocol/sponsor instruction, returned or destroyed with documentation, and the investigator/institution has notified (or is arranging to notify) the IRB/REB of study closure at that site.
Randomization Methods in Clinical Trials
A randomization method is the pre-specified, reproducible procedure by which a clinical trial assigns each participant to a treatment or control arm based on chance rather than on the choice of the investigator, the participant, or any deterministic rule (e.g., alternating assignment or day-of-week). A procedure qualifies as randomization only if the allocation sequence is generated by a chance mechanism, is concealed from whoever enrolls participants until after enrollment (allocation concealment), and is documented so the trial's statistical analysis plan can account for it. The choice of method -- simple, block, stratified, or covariate-adaptive -- determines how tightly the resulting treatment groups are balanced on sample size and on prognostic factors, but all four share the same underlying purpose described by ICH E9, Statistical Principles for Clinical Trials: minimizing selection bias in treatment assignment and providing a sound statistical basis for comparing groups.
Decentralized Clinical Trials (DCTs)
A clinical trial is decentralized to the extent that trial-related activities normally performed at an investigational site — participant visits, specimen collection, investigational product dispensing, or outcome data collection — are instead performed via telehealth, a local lab/imaging facility or visiting health-care provider, direct-to-participant shipment, or a digital health technology, while the same IND/IDE, GCP, informed-consent, and safety-reporting requirements continue to apply. DCTs range on a spectrum from hybrid (some site visits, some remote) to fully decentralized (no in-person site visits).
Umbrella Trial
An umbrella trial is a clinical trial design in which multiple investigational therapies are evaluated within a single disease population under one overarching master protocol, with each treatment arm matched to a different biomarker or molecular subtype found within that disease. The disease is held constant across the trial; the drug arm assigned to a given patient varies according to the biomarker their tumor or condition carries. FDA formally recognizes the umbrella trial as one of three related master-protocol designs, alongside the basket trial and the platform trial, in its guidance on master protocols for oncology drug and biologic development.
Endpoint Adjudication Committee (CEC)
An Endpoint Adjudication Committee (EAC) — often called a Clinical Events Committee (CEC) — is an independent group of clinical experts, typically blinded to each participant's treatment assignment, that reviews reported clinical events (deaths, hospitalizations, strokes, myocardial infarctions, and other complex or subjective outcomes) against pre-specified, standardized criteria defined in the trial protocol and a dedicated adjudication charter, and issues a formal, documented determination of whether each event meets the definition of a study endpoint. Adjudication exists to remove site-to-site and investigator-to-investigator variability in how an outcome gets diagnosed and classified — a real risk whenever the endpoint depends on clinical judgment rather than a single objective lab value — and it is a distinct function from safety oversight: a CEC classifies individual events against fixed criteria, it does not conduct comparative interim analyses across arms or recommend stopping the trial.
Estimand Framework
The estimand framework, introduced in the ICH E9(R1) addendum to 'Statistical Principles for Clinical Trials' (final version adopted November 2019), is the structured approach a clinical trial protocol uses to state precisely, before the trial is analyzed, what treatment effect the trial is actually designed to estimate. A trial's estimand is defined by specifying five attributes: (1) the target population (the patients the clinical question is about), (2) the treatment conditions being compared, (3) the variable or endpoint measured for each participant, (4) the strategy for handling intercurrent events -- post-randomization events, such as treatment discontinuation, use of rescue medication, or death, that affect either the interpretation or the existence of the planned measurement -- and (5) the population-level summary used to compare the treatment conditions (for example, a difference in means, an odds ratio, or a hazard ratio). A trial only has a well-defined estimand when all five attributes are specified together and agreed before unblinding; changing how one attribute is handled (most consequentially, the intercurrent-event strategy) changes what the resulting number actually means, even if the same raw data and the same statistical test are used to produce it.
Assent (in Research)
Assent is the affirmative agreement of a prospective research subject who lacks the legal capacity to give informed consent on their own behalf — typically a minor — to take part in a research study. Under 45 CFR 46 Subpart D (§46.402(b), §46.408), assent is distinct from, and required in addition to, the informed permission of a parent or legally authorized guardian: a child's willingness to participate does not substitute for parental permission, and parental permission does not substitute for the child's own assent where an Institutional Review Board (IRB) has determined the child is capable of providing it. Critically, assent must be an affirmative 'yes' — the regulation explicitly states that a child's mere failure to object, absent some affirmative agreement, may not be construed as assent. The IRB decides, on a study-by-study or even subject-by-subject basis, whether assent is required, how it should be solicited (verbally, in writing, or via an age-appropriate script), and whether it may be waived under the conditions set out in §46.408(a).
Interim Monitoring Visit (IMV)
<p>An Interim Monitoring Visit (IMV) -- also called a routine monitoring visit or periodic site monitoring visit -- is a monitoring contact, on-site or remote, that a sponsor or its designated Clinical Research Associate (CRA) conducts at intervals throughout the active conduct phase of a clinical trial, after a site has been initiated and is enrolling or following participants, and before the site closes out. Its purpose, per ICH E6(R2) Section 5.18.3, is to verify that the rights and well-being of trial participants are protected, that reported trial data are accurate, complete, and verifiable from source documents, and that the trial is being conducted in compliance with the currently approved protocol/amendments, Good Clinical Practice (GCP), and applicable regulatory requirements. A contact only qualifies as an IMV if it occurs during this ongoing conduct period and covers the recurring monitoring activities -- source data verification, investigational product (IP) accountability, regulatory-document currency, and safety-reporting checks -- described below; a visit conducted before a site has enrolled its first participant, or after the site has permanently stopped activity, falls under a different visit type instead.</p>
Registrational Trial
A registrational trial (also called a pivotal trial) is a clinical study designed and executed specifically to generate the primary efficacy and safety evidence submitted in a marketing application — a New Drug Application (NDA), Biologics License Application (BLA), or comparable submission — to a regulatory authority such as FDA. What makes a trial ‘registrational’ is not its phase number but its regulatory purpose: it is prospectively designed as an adequate and well-controlled investigation under 21 CFR 314.126, with a prespecified primary endpoint and statistical analysis plan agreed with the regulator (often via a Special Protocol Assessment), and powered to provide the ‘substantial evidence of effectiveness’ the Federal Food, Drug, and Cosmetic Act requires for approval. Most registrational trials are Phase 3 studies, but a well-controlled Phase 2 trial can serve the same function in accelerated-approval or rare-disease programs where a full Phase 3 program is used to confirm benefit post-approval.
Site Qualification Visit (SQV)
A Site Qualification Visit (SQV) is the pre-selection assessment visit a sponsor or CRO conducts at a prospective investigative site, before that site is contracted or selected for a specific clinical trial, to evaluate whether it should be chosen. A visit counts as an SQV when its purpose is evaluative and its timing is pre-selection: it examines the site's facilities and equipment, staff qualifications and prior trial experience, patient population and recruitment feasibility, and quality systems/SOPs, in order to inform a go/no-go selection decision. A visit is NOT an SQV if it occurs after the site has already been selected, contracted, and IRB-approved and is instead confirming the site is ready to begin enrollment -- that is a Site Initiation Visit (SIV) -- or if it occurs during active enrollment to review ongoing conduct, which is a routine monitoring visit.
Bayesian Adaptive Design
A Bayesian adaptive design is a clinical trial design in which the statistical framework starts from a prior probability distribution over treatment effects and formally updates that distribution into a posterior distribution as outcome data accumulate during the trial, using Bayes' theorem rather than waiting for a single fixed-sample-size final analysis. What makes a design specifically Bayesian-adaptive, rather than merely adaptive, is that the pre-specified adaptation rules (whether to modify randomization allocation, stop a trial arm early for efficacy or futility, or re-estimate sample size) are driven by these continuously updated posterior probabilities rather than by frequentist p-value or alpha-spending boundaries alone. The most common operational form is Bayesian response-adaptive randomization: the probability that a newly enrolled participant is assigned to a given arm shifts over the course of the trial toward arms whose posterior probability of superiority is higher, based on outcomes observed so far in the shared, concurrently randomized control comparison. This distinguishes a Bayesian adaptive design from a conventional frequentist fixed-sample design, in which the randomization ratio and total sample size are fixed at the outset by a power calculation and the treatment-effect hypothesis is tested once, at a single pre-planned analysis (or at a small number of pre-specified interim looks using a fixed alpha-spending function), with no allocation-ratio changes based on relative arm performance mid-trial.
Pre-Screening
Pre-screening is the informal, preliminary process of assessing whether a prospective clinical trial participant is likely to meet inclusion/exclusion criteria, conducted before the protocol-defined formal screening visit and generally before the participant signs the informed consent form (ICF). It typically takes the form of a brief phone or in-person eligibility interview using an IRB-approved script, or a review of existing medical records/EHR data conducted under a HIPAA waiver of authorization or the reviews-preparatory-to-research provision (45 CFR 164.512(i)). A candidate excluded at this stage never enters the trial's formal screening and enrollment log and is not counted toward the trial's screen failure rate.
HREC (Human Research Ethics Committee)
The Australian term for the committee that reviews and approves research involving human participants before it may lawfully or ethically proceed. An HREC is constituted and registered under the National Health and Medical Research Council (NHMRC)'s National Statement on Ethical Conduct in Human Research, and its review is the Australian institutional counterpart to an IRB (Institutional Review Board) in the United States or an REC (Research Ethics Committee) in the UK/EU. A study is subject to HREC review whenever it involves human participants, their identifiable data, or their tissue and is designed to produce generalisable knowledge; the depth of that review is graded by risk rather than uniform for every protocol.
Screen Failure
A participant who provides informed consent and enters the protocol-defined screening process for a clinical trial, but is not subsequently randomized or assigned to study intervention because they fail to meet one or more inclusion/exclusion criteria, withdraw consent before randomization, or otherwise become ineligible prior to enrollment. The defining boundary is randomization/assignment to study intervention: everything before that point that ends without assignment is a screen failure; anything after it is a post-randomization withdrawal or discontinuation, not a screen failure.
Equivalence Trial
An equivalence trial is a clinical trial designed to show that a new intervention's effect is neither meaningfully better nor meaningfully worse than an active comparator -- the treatment difference must fall within a pre-specified equivalence margin in both directions. It is one of three ways a comparative trial's primary hypothesis can be framed at the protocol design stage: a superiority trial sets out to show one arm is better than another (or than placebo); a non-inferiority trial sets out to show a new arm is not unacceptably worse than an active comparator, using only a single lower margin; an equivalence trial requires the treatment difference's confidence interval to fall entirely within a symmetric two-sided margin, written (-delta, +delta), that was fixed before the trial started as the largest difference still considered clinically unimportant. Which of the three applies is a design decision documented in the protocol and statistical analysis plan -- it is not something inferred after the fact from a trial's results.
Study Data Tabulation Model (SDTM)
The Study Data Tabulation Model (SDTM) is a CDISC foundational standard that defines a standard structure for organizing clinical trial data into a set of named, model-conformant domain datasets (e.g. DM, AE, VS) for submission to regulatory authorities such as the FDA and Japan's PMDA. A dataset counts as SDTM-conformant when its observations are classified into one of SDTM's general observation classes (Interventions, Events, Findings, or Findings About), each variable maps to a controlled SDTM domain/variable name, and the dataset is accompanied by a define.xml metadata file describing its structure. SDTM governs the submission-ready tabulation format, not how data is collected at the site (that is CDASH) and not the software used to capture it (that is EDC).
Cross-Sectional Study
A cross-sectional study is an observational research design in which exposure and outcome (or any set of variables) are measured on a defined sample at a single point in time, rather than by following participants forward or reconstructing their history backward. Participants are selected on inclusion/exclusion criteria for the population of interest, not on their exposure or outcome status -- that selection rule is what separates a cross-sectional design from a cohort study (selected on exposure, followed forward) or a case-control study (selected on outcome, examined retrospectively). Because everything is captured in a single snapshot, a cross-sectional design can describe prevalence and association but cannot, on its own, establish temporal sequence or causation.
Platform Trial
A platform trial is a clinical trial conducted under a single master protocol that evaluates multiple interventions against a shared control arm, for a single disease or condition, on a perpetual or long-running basis — arms can be added or dropped over time as interventions are found effective, futile, or superseded, without stopping the trial and writing a new protocol from scratch. The FDA's 2018/2022 master-protocol guidance groups platform trials alongside two related but distinct designs sharing the same master-protocol infrastructure: <a href='/dictionary/term/basket-trial'>basket trials</a> (one intervention tested across multiple diseases or molecular subtypes) and umbrella trials (multiple interventions tested for one disease, but with a fixed, pre-specified set of arms rather than an open-ended one). What makes a design a platform trial specifically, rather than a generic multi-arm study, is the combination of (1) a single overarching master protocol and statistical analysis plan governing all arms, (2) a shared, concurrently randomized control group that multiple experimental arms are compared against, and (3) a pre-specified adaptive mechanism — typically Bayesian response-adaptive randomization or interim futility/efficacy stopping rules — for adding, dropping, or reallocating arms as data accumulate.
Electronic Clinical Outcome Assessment (eCOA)
The technology/platform category (provisioned device, BYOD app, IVR/IWR, or site-based terminal) used to capture Clinical Outcome Assessment (COA) data — PRO, ClinRO, ObsRO, or PerfO — electronically at the point of assessment, in place of a paper case-report form, typically requiring mode-of-administration equivalence to the original paper instrument and 21 CFR Part 11-consistent audit trails/access controls before the resulting data is relied on for a trial endpoint.
Late-Phase Clinical Study
A late-phase clinical study is a Phase IIIb or Phase IV clinical investigation of a drug or biologic conducted at, or just after, regulatory marketing submission or approval, rather than during the pre-approval IND-governed Phase 1-3 sequence defined at 21 CFR 312.21. Late-phase studies do not primarily generate the initial efficacy/safety data needed for approval; instead they expand the evidence base after (or just before) approval, supporting label expansion, fulfilling FDA-mandated Postmarketing Requirements (PMRs) or voluntary Postmarketing Commitments (PMCs), and generating real-world evidence (RWE) and pharmacovigilance data on an approved product's safety and effectiveness in broader, real-world populations.
Sub-Investigator
A sub-investigator is a member of a clinical trial site team who is designated and supervised by the principal investigator (PI) to perform critical trial-related procedures and/or make important trial-related decisions, without themselves holding overall responsibility for the trial's conduct at that site. Under FDA regulations, the PI signs the <a href='/dictionary/term/fda-form-1572'>FDA Form 1572 (Statement of Investigator)</a> and lists sub-investigators by name as persons assisting in the investigation (21 CFR 312.53(c)); sub-investigators do not sign the 1572 themselves. What specific duties a given sub-investigator is authorized to perform is documented separately, on the site's <a href='/dictionary/term/delegation-of-authority-log'>Delegation of Authority (DoA) log</a>, which the PI is responsible for maintaining under ICH E6(R2) Section 4.1.5. Common sub-investigator duties include obtaining informed consent, conducting protocol-specified assessments, and making eligibility or safety-related clinical judgments -- but the PI retains ultimate accountability for the trial's conduct at the site under 21 CFR 312.60, regardless of which duties are delegated.
Good Clinical Data Management Practices (GCDMP)
A clinical data management (CDM) process, procedure, or document is following Good Clinical Data Management Practices (GCDMP) when it is explicitly built against a specific chapter of SCDM's published GCDMP document -- covering an area such as CRF/eCRF design, database design and validation, discrepancy management, medical coding, database lock, or data transfer/archival -- and can be shown to meet that chapter's Minimum Standards tier (the baseline for defensible CDM) or its Best Practices tier (a higher-maturity level beyond the minimum). GCDMP is a practice/process standard, not software: an EDC or CDMS platform is the technology a GCDMP-conformant process typically runs through, not GCDMP itself.
Source Data Verification (SDV)
<p>Source data verification (SDV) is the clinical-trial monitoring activity of comparing data entered on a case report form (CRF or eCRF) against the source document it was transcribed from -- a clinic note, hospital chart, lab report, imaging read, ECG tracing, or participant diary -- to confirm that the CRF entry is accurate, complete, and consistent with the original record. SDV checks a specific, already-transcribed value against its origin; it is a monitoring/quality-control activity, not a data-entry platform. Neither ICH E6 nor FDA guidance has ever required verifying 100% of CRF fields against source; since the early 2010s, regulatory guidance has explicitly encouraged sponsors to target SDV, as part of a broader risk-based monitoring (RBM) strategy, toward the data most critical to participant safety and primary trial endpoints rather than exhaustively verifying every field by default.</p>
Decentralized Clinical Trial (DCT) Platform
A decentralized clinical trial (DCT) platform is the software and connected-service layer that lets some or all trial activities happen away from a traditional investigative site, in line with FDA's trial-conduct model for decentralized elements. In practice a DCT platform is not one thing but an integration of several components under a single participant- and site-facing interface: telehealth/video-visit tooling for remote investigator encounters, eConsent for remote informed consent, home health or mobile-nursing coordination for in-home visits and specimen collection, connections to local or community labs and pharmacies as alternate data-collection or dispensing sites, direct-to-patient (DtP) investigational product (IMP) shipment and chain-of-custody tracking, and eCOA/ePRO or connected devices for participant-reported and sensor-derived data — usually feeding a central EDC and safety database in real time. A trial "uses a DCT platform" when a vendor's connected toolset, rather than a single point solution, is the operational backbone for how remote or hybrid visits are scheduled, conducted, documented, and reconciled against the protocol. The defining administrative complication is that decentralizing activities does not decentralize accountability: the sponsor and the trial's IRB(s) of record remain responsible for GCP compliance, and each local nurse, telehealth clinician, lab, or pharmacy performing a delegated trial activity must be added to the delegation-of-authority log, must practice within a jurisdiction where they are licensed, and must be covered by the same monitoring and oversight expectations as staff at a traditional site.
IDE Application (Investigational Device Exemption Application)
An IDE application is the formal submission a sponsor files with FDA's Center for Devices and Radiological Health under 21 CFR 812.20 to request an Investigational Device Exemption -- FDA authorization to ship and use an unapproved medical device in a clinical study before it has been cleared or approved for commercial distribution. A full IDE application, and FDA's affirmative or default clearance to proceed, is required only for significant risk (SR) device investigations; nonsignificant risk (NSR) studies proceed on abbreviated requirements reviewed by the IRB, without a separate FDA-submitted application.
Paediatric Investigation Plan (PIP)
A Paediatric Investigation Plan (PIP) is the development plan a sponsor must agree with the European Medicines Agency's Paediatric Committee (PDCO) before an EU marketing authorisation application (MAA) can be validated, under Regulation (EC) No 1901/2006. It sets out the studies, age-appropriate formulations, and timelines needed to support use of a medicine in children, and applies to new active substances and to new indications, pharmaceutical forms, or routes of administration for already-authorised products that are still under patent or supplementary protection certificate (SPC) protection. A product is only exempt from the PIP requirement if it has a PDCO-granted waiver (full or class), if it is a generic, well-established-use, homeopathic, or traditional-herbal application under Article 10 of Directive 2001/83/EC, or if all paediatric studies are formally deferred to a later stage of development while the PIP itself is still agreed and on file.
Basket Trial
A basket trial is a clinical trial design, formalized by FDA as one of three master-protocol types, that tests a single investigational drug (or drug combination) across multiple disease populations that are grouped not by their tissue of origin but by a shared molecular alteration or biomarker. In oncology, where the design is most established, a basket trial enrolls patients with different cancer types — lung, colorectal, melanoma, and others — into a common protocol as long as their tumors share a specified genomic alteration, and treats them with the same targeted therapy regardless of where the cancer originated. A study qualifies as a basket trial when three conditions hold together: (1) a single drug or drug combination is under evaluation, (2) enrollment is organized around a shared biomarker or molecular subtype rather than a single disease, and (3) the protocol spans what would otherwise be treated as separate diseases or histologies. Basket trials are typically single-arm and use overall response rate as the primary endpoint, since a shared, adequately characterized control group across multiple diseases is often impractical.
Medical Writing in Clinical Trials
Medical writing in clinical trials is the specialized discipline of drafting, editing, and maintaining the regulatory and clinical documents that a trial produces from protocol design through final reporting -- protocols and protocol amendments, Investigator's Brochures (IB), informed consent forms (ICF), Clinical Study Reports (CSRs), the clinical sections of regulatory submissions (e.g. the Common Technical Document modules submitted to FDA, EMA, or other regulators), and trial-related publications such as journal manuscripts, congress abstracts, and plain-language summaries. A document counts as an instance of medical writing in this sense when (a) it is a formal, structured deliverable required or expected at a defined point in the trial lifecycle, (b) it must accurately represent clinical and statistical content that the writer did not personally generate, and (c) it is produced to a recognized structural or ethical standard -- most commonly ICH E3 for CSRs, ICH E6 for protocol and consent-related content, and the Good Publication Practice (GPP 2022) guidelines for publication-related writing -- rather than being general-purpose scientific or lay writing about a trial.
45 CFR 46 Subpart D (Additional Protections for Children in Research)
The section of the Common Rule (45 CFR 46, §§46.401-46.409) that governs HHS-conducted or HHS-funded research involving children as subjects. A protocol falls under Subpart D whenever its subjects have not attained the legal age for consent to the research procedures under the law of the jurisdiction where the research will be conducted (§46.402). The IRB must classify the protocol into one of four risk categories -- no greater than minimal risk (§46.404), greater than minimal risk with prospect of direct benefit (§46.405), greater than minimal risk with no direct benefit but likely generalizable knowledge (§46.406), or research not otherwise approvable that HHS’s Secretary determines addresses a serious child-health problem (§46.407) -- and must determine what combination of parental/guardian permission and child assent is required under §46.408 before approving it.
Wearable Devices and Digital Health Technologies (DHTs) in Clinical Trials
<p>A digital health technology (DHT) is defined by FDA as a system that uses computing platforms, connectivity, software, and/or sensors for healthcare and related purposes, used to collect, store, and transmit health-related data. In a clinical trial, a device or software is functioning as a DHT specifically when it is used to remotely acquire data from or about a participant that will be used to support a trial endpoint or otherwise inform a regulatory decision — not merely as a convenience app or a participant engagement tool with no bearing on the data package submitted to a regulator. Wearables (heart rate trackers, actigraphy bands, continuous glucose monitors) are the most visible category, but the term also covers non-worn sensors, implantables, and participant-facing mobile apps that capture symptom or functional data, provided that data feeds into the trial's endpoints or safety monitoring. What distinguishes a DHT from an ordinary electronic data-capture tool is the verification and validation burden it creates: a sponsor must demonstrate the technology reliably captures the intended clinical event or physiological parameter, in the population and context of actual use, before that data can support a trial conclusion.</p>
TransCelerate GCP Mutual Recognition Program
The TransCelerate GCP Mutual Recognition Program is an industry framework, run by TransCelerate BioPharma (a nonprofit collaboration of biopharmaceutical sponsor companies), under which Good Clinical Practice (GCP) training completions from a recognized training provider are accepted by multiple participating sponsor companies rather than each sponsor requiring its own separate GCP training for the same investigator or site staff member. It sits within TransCelerate's Site Qualification and Training (SQT) initiative, which targets the duplicative questionnaires, forms, and training courses that clinical trial sites have historically had to complete separately for each sponsor and, in some cases, for each individual trial. A GCP training provider participates by self-attesting that its course meets minimum criteria aligned with ICH E6 Good Clinical Practice; providers that meet the criteria have their courses made available through TransCelerate's Shared Investigator Platform (SIP), where site staff can complete training once, upload the resulting certificate, and have participating sponsors retrieve and accept it during study start-up instead of re-verifying or re-issuing training separately. A record is a genuine instance of the program when the underlying GCP course completion was issued by a provider recognized under TransCelerate's mutual-recognition criteria and is being accepted, without separate re-training, by a second (or subsequent) participating sponsor company for a different trial or company relationship -- not merely any GCP-aligned course completion in general.
Medical Monitor (Clinical Trials)
A Medical Monitor is the physician (or other appropriately qualified clinician) designated by a clinical trial sponsor or its CRO to provide ongoing, cross-site medical and safety oversight: reviewing accumulating adverse events for causality and expectedness, answering investigators' medical eligibility and protocol-interpretation questions, and flagging safety signals for the sponsor or a DSMB. The role requires medical qualification, sponsor-side (not site-based) placement with no direct participant-care relationship, and cross-site safety-judgment scope — it is a de facto function of the sponsor's safety obligations under ICH E6 and 21 CFR 312.32 rather than a term either formally defines in its own glossary.
Blinding and Masking in Clinical Trials
Blinding (or masking, the term FDA/ICH guidance now prefer) in a clinical trial is the procedure of keeping one or more trial parties -- the participant, the investigator/care provider, the outcomes assessor, and/or the data analyst -- unaware of which treatment arm a given participant was assigned to, from the point of randomization onward. It is recorded on ClinicalTrials.gov as the "Masking" data element with levels of None (open-label), Single, Double, Triple, or Quadruple, depending on how many of those roles are kept unaware. Masking is a distinct methodological safeguard from randomization and allocation concealment: it addresses performance bias (differential behavior or care from knowing the assignment) and detection/ascertainment bias (differential outcome judgment), not selection bias at enrollment.
Data Safety Monitoring Plan (DSMP)
A <strong>Data Safety Monitoring Plan (DSMP)</strong> is the written document a study team develops -- usually as part of a grant application or protocol package, before a trial opens -- describing exactly how participant safety data will be monitored throughout the study: who will review the data, how often, what will be reviewed, the mechanism for reporting adverse events to the IRB, the funding agency, and (where applicable) the FDA, and the stopping rules that would trigger pausing or ending the trial. Every NIH-funded clinical trial must have a DSMP, scaled to the trial's size, complexity, and risk -- but not every DSMP requires a full independent Data Safety Monitoring Board (DSMB). A DSMP is the plan document itself; a DSMB is one possible monitoring mechanism a DSMP can specify. For lower-risk trials, the DSMP more commonly designates the principal investigator or an independent safety monitor/medical monitor as the reviewer instead of convening a formal board.
eSource (Electronic Source Data)
Electronic source data (eSource) is clinical trial data that is first recorded in electronic form at the point of observation -- typed directly into an electronic health record (EHR), an electronic patient-reported outcome (ePRO) or clinical outcome assessment (eCOA) device, or directly into an EDC system during a study visit -- rather than being first written on paper (a clinic note, a lab printout, a paper diary) and later transcribed into an electronic system. The origination point, not the software used to store or display the data, is what makes a given data point eSource: the same EDC platform can hold both eSource data (entered live, not transcribed) and non-eSource data (transcribed from a paper source document) within the same study.
IRB Coordinator
The <strong>IRB Coordinator</strong> (also called IRB Administrator, IRB Analyst, or Human Subjects Protection Coordinator, depending on the institution) is the staff role responsible for the administrative and operational running of an Institutional Review Board (IRB) office — protocol intake and completeness review, meeting scheduling and logistics, correspondence with investigators, tracking continuing-review and other regulatory deadlines, and maintaining the IRB's official records. It is a non-voting, non-determination-making role: the Coordinator supports the board's process but does not review protocols for approval, does not preside over convened meetings, and does not carry the IRB Chair's statutory authority to make or assign expedited-review determinations under 45 CFR 46.110 / 21 CFR 56.110.
Clinical Trial Central Laboratory
A clinical trial central laboratory is a single designated laboratory, or a network of laboratories operating under one standardized protocol, contracted to perform sample testing (e.g., blood chemistry, hematology, biomarker assays, pharmacokinetic analysis) for every investigative site in a multi-site trial, rather than each site using its own local or institutional lab. A vendor relationship qualifies as a central laboratory arrangement when it provides all of: (1) a single set of standardized testing protocols, equipment, and reference ranges applied uniformly across every participating site; (2) site-facing logistics -- specimen collection kits, labeled containers, and standardized courier/shipping arrangements -- so specimens from geographically dispersed sites reach the same analytical instruments; and (3) pooled, harmonized result reporting back into the trial's data set, so that a lab value from Site A and the equivalent value from Site B were generated by the same method and are directly comparable without a site-specific correction factor.
Commercial IRB
A commercial IRB (also called an independent IRB) is an Institutional Review Board that operates as a standalone, for-profit or non-profit business providing human-subjects ethics review as a paid, fee-for-service function -- rather than as an internal department of the university, hospital, or research institution whose studies it reviews. It is registered with OHRP and, for FDA-regulated research, meets the same 21 CFR Part 56 requirements as any other IRB; the distinguishing feature is organizational independence and a client-billing relationship with the sites and sponsors it reviews for, not a lower regulatory bar. Commercial IRBs (WCG/WIRB and Advarra are the two largest in the U.S. market) are frequently designated as the single IRB (sIRB) of record for multi-site trials, but sites also route single-site industry-sponsored studies to a commercial IRB even when no sIRB mandate applies -- typically because the sponsor requires it, the site has no local IRB, or the site's own IRB lacks capacity or relevant expertise for the study type.
UPIRSO (Unanticipated Problem Involving Risks to Subjects or Others)
A UPIRSO is an incident, experience, or outcome in human subjects research that meets all three of OHRP’s reporting criteria: it is unexpected in nature, severity, or frequency given the protocol and subject population; it is related or possibly related to participation in the research; and it suggests subjects or others face greater risk of harm than was previously known. All three prongs must be met — an event failing any one of them is not a UPIRSO under OHRP guidance, even if it is still reportable under another category such as a routine adverse event or protocol deviation. The investigator reports a suspected UPIRSO promptly to the IRB per 21 CFR 56.108(b) (FDA-regulated research) and the institution’s Federalwide Assurance procedures (federally-supported research generally); the institution may then have a further obligation to report certain UPIRSOs to OHRP and the supporting federal agency, on a timeframe set by its own written policies rather than one fixed federal number of days.
Model Clinical Trial Agreement (mCTA)
A Model Clinical Trial Agreement (mCTA) is a standardized, pre-negotiated template Clinical Trial Agreement published by a national body, funder, or multi-institutional consortium, and intended to be used with little or no clause-by-clause negotiation for each new trial. Adopting sponsors and sites fill in trial-specific variables (protocol reference, budget schedule, site details) against core legal language -- indemnification, IP allocation, publication rights, data ownership -- both sides have already pre-agreed is acceptable. It is defined by the contracting strategy (a fixed starting point institutions commit in advance to accept largely unmodified), not by any single clause, since CTA content itself varies by jurisdiction.
42 CFR Part 11
42 CFR Part 11 is the federal regulation, titled "Clinical Trials Registration and Results Information Submission," that codifies the ClinicalTrials.gov registration and results-reporting requirements originally created by Section 801 of the Food and Drug Administration Amendments Act of 2007 (FDAAA 801). Issued by HHS as a Final Rule and effective 18 January 2017 (compliance expected by 18 April 2017), it converts FDAAA 801's statutory mandate into binding, enforceable regulatory text: who counts as the "responsible party" for a trial, which trials are "applicable clinical trials" (ACTs) subject to the rule, the specific data elements and deadlines for registration and results submission, and FDA's civil monetary penalty authority for noncompliance. A trial is governed by 42 CFR Part 11 only if it meets the regulation's ACT definition; broader definitions used by ICMJE or by NIH's own separate results-reporting policy can require registration or reporting for trials that fall outside Part 11's narrower scope.
Adverse Event of Special Interest (AESI)
An Adverse Event of Special Interest (AESI) is an adverse event (serious or non-serious) that a trial sponsor pre-identifies in the study protocol as being of scientific and medical concern specific to the investigational product or research programme, because there is a known or suspected mechanistic, class-effect, or prior-safety-signal reason to watch for it. Unlike a general Adverse Event (AE), which is simply any untoward medical occurrence observed during a trial, an AESI is defined in advance, by name, before the first participant is enrolled -- the protocol (and often a companion safety monitoring plan) lists the specific event, the case definition or diagnostic criteria used to confirm it, and the enhanced procedures for capturing it (e.g. dedicated case report form fields, expedited investigator-to-sponsor reporting timelines, or independent adjudication by a clinical events committee). Because the AESI designation is about the *reason for watching*, not the event's clinical severity, an AESI can be non-serious under the ordinary ICH E2A seriousness criteria (death, life-threatening, hospitalization, persistent disability, congenital anomaly, or 'otherwise medically important') and still trigger the same rapid-reporting and characterization procedures a serious event would. This is the operational test for whether something is an AESI: was it named as a specific event of concern in the protocol/safety monitoring plan before enrollment began, for a documented scientific or regulatory reason -- as opposed to emerging unexpectedly during the trial.
Clinical Trial Protocol
A clinical trial protocol is the formal, version-controlled document that defines a study's rationale, objectives, design, methodology, statistical considerations, and organization -- specifying eligibility criteria, interventions, assessments/procedures and their timing, endpoints, and the responsibilities of investigators and sponsors. Under ICH E6(R3), it is the controlling document that IRB/ethics committee review, investigator conduct, sponsor oversight, and (once locked) the statistical analysis all reference; any conduct outside its terms requires either an approved amendment or documented justification as an immediate-safety deviation.
Investigational New Drug (IND)
A drug or biologic that FDA has authorized, via an active IND application under 21 CFR Part 312, to be shipped and administered to human subjects in a clinical investigation before it has received marketing approval — or an already-approved drug being studied outside the bounds of its approved labeling in a way that meets the triggering criteria in 21 CFR 312.2(b). The term refers interchangeably to the drug's regulatory status, the sponsor's application establishing that status, and the FDA-assigned number the study operates under.
45 CFR 164.512(i) (HIPAA Uses and Disclosures for Research Purposes)
The provision of the HIPAA Privacy Rule, at 45 CFR 164.512(i), that permits a covered entity to use or disclose protected health information (PHI) for research without the individual's written authorization, through one of three specific pathways: (1) an Institutional Review Board (IRB) or Privacy Board has approved a waiver or alteration of authorization under the documented criteria at 164.512(i)(1)(i) and (i)(2); (2) the researcher represents the use is solely a review preparatory to research and no PHI will be removed from the covered entity; or (3) the researcher represents the use is solely for research on a decedent's information. A disclosure only qualifies under 164.512(i) if it fits one of these three pathways exactly as documented — it is not a general research exception.
Case Report Form (CRF)
A case report form (CRF) is the study-specific data-collection instrument -- paper or electronic (eCRF) -- through which a clinical trial's protocol-defined data points are recorded for each participant and transmitted to the sponsor or its designee for analysis. Its content is derived directly from the protocol and the Statistical Analysis Plan: every field on a CRF should map to a specified assessment, visit, or endpoint, and nothing should appear on a CRF that isn't required by the protocol. Data recorded on a CRF must be verifiable against source documents (the original records -- clinic charts, lab reports, imaging, ECGs, patient diaries -- where a data point was first captured), a process called source data verification (SDV). ICH E6(R2)/(R3) hold the CRF to the same data-integrity expectations that apply to source data generally, commonly summarized by the ALCOA+ attributes (attributable, legible, contemporaneous, original, accurate, plus complete, consistent, enduring, available); any correction made after initial entry must preserve an audit trail rather than overwrite the original value. CRF field design commonly follows CDISC's CDASH standard to ease downstream mapping to SDTM submission datasets. A CRF is a distinct concept from a published case report (a journal article type describing an unusual clinical case) despite the similar name.
ISRCTN
<p>ISRCTN — originally an acronym for International Standard Randomised Controlled Trial Number, now used as the registry's own name — is a UK-based clinical study registry that assigns a permanent, unique identifier (an ISRCTN number) to a study at or before its start. A study qualifies as "ISRCTN-registered" when its investigator or sponsor has submitted the required minimum data set (design, intervention, population, primary/secondary outcomes, sponsor, funder) through isrctn.com, the entry has passed the registry's validation checks, and it has been assigned a permanent identifier in the format ISRCTN followed by an eight-digit number (for example, ISRCTN12345678). Unlike its original RCT-only scope, ISRCTN now accepts any study assessing the effect of a health intervention on a human population, including non-randomised interventional studies and some observational designs — the acronym is retained for historical/branding reasons but no longer describes the registry's actual scope.</p>
eConsent (Electronic Informed Consent)
eConsent (electronic informed consent) is the use of an electronic system, often incorporating multimedia such as video or interactive comprehension checks, to present IRB-approved informed consent information and capture a participant's electronic signature in place of a paper form. A process counts as eConsent when it delivers the required consent content electronically, preserves a genuine opportunity for the participant to ask questions before signing, captures an attributable electronic signature that is time-stamped and non-detachably linked to the specific document version reviewed, and provides the participant a copy of the signed consent. For FDA-regulated clinical investigations, the electronic signature must meet 21 CFR Part 11's criteria; FDA and OHRP's December 2016 joint guidance additionally recommends that IRBs review the electronic process and interface itself, not just the consent language.
Study Identifier
The unique code a registry assigns to identify a specific research study — a clinical trial, systematic review, or other registered research project — as that study itself, distinct from an identifier assigned to one of its resulting outputs (a DOI), its underlying dataset, or an individual researcher (an ORCID iD). A study identifier's format, prefix, and issuing authority are registry-specific: ClinicalTrials.gov assigns 'NCT' numbers, the ISRCTN registry assigns 'ISRCTN' numbers, and PROSPERO assigns 'CRD42' numbers. A single study can carry more than one study identifier if it is registered, or cross-registered, in more than one registry.
Priority Review Voucher (PRV)
A priority review voucher (PRV) is a transferable FDA incentive awarded when a sponsor wins approval of a qualifying drug or biologic under the rare pediatric disease PRV program (FD&C Act section 529) or the tropical disease PRV program (FD&C Act section 524). The voucher lets its holder — the original sponsor or a company it is sold to — redeem it for priority review (a six-month FDA review goal) instead of standard review (a ten-month goal) on a different, later marketing application.
Placebo-Controlled Study Design
A placebo-controlled study is an interventional design in which one or more comparator arms receive an inert or sham intervention (a placebo) instead of, or in addition to, the intervention under investigation, so that any outcome difference between arms can be attributed to the study intervention itself rather than to the act of receiving treatment, participant or investigator expectation, natural disease fluctuation, or regression to the mean. It is one of the standard concurrent-control-group categories set out in ICH E10, alongside no-treatment control, dose-response control, active (positive) control, and external/historical control, and it is most often paired with randomization and blinding so that neither participants nor assessors know which arm a given participant is in.
MedDRA (Medical Dictionary for Regulatory Activities)
MedDRA (Medical Dictionary for Regulatory Activities) is the standardized, five-level hierarchical medical terminology -- System Organ Class, High Level Group Term, High Level Term, Preferred Term, and Lowest Level Term -- used to code adverse events, symptoms, diagnoses, and other clinical findings for entry into clinical trial databases and electronic submission to regulators. Developed under ICH and maintained by the MSSO, a MedDRA-coded term is required for electronic individual case safety report (ICSR) submission across ICH-region regulators.
Complete Response Letter (CRL)
A Complete Response Letter (CRL) is a formal notice FDA sends a sponsor, under 21 CFR 314.110, stating that a New Drug Application, Biologics License Application, or efficacy supplement will not be approved in its present form. It is distinct from a refusal to file (issued before review begins) and from an outright, final rejection: the sponsor may resubmit after addressing the cited deficiencies, withdraw the application, or request a hearing.
Clinical Research
Clinical research is the umbrella term for any systematic investigation involving human participants, or material of human origin traceable to a living individual, that is designed to generate generalizable knowledge about human health or disease. Per NIH's own definition, it spans three broad categories: (1) patient-oriented research, where an investigator directly interacts with human subjects to study disease mechanisms, therapeutic interventions, clinical trials, or new technologies; (2) epidemiologic and behavioral studies; and (3) outcomes research and health services research. A clinical trial is only one subset within the first category — specifically, patient-oriented research in which participants are prospectively assigned to an intervention. Clinical research as a whole also includes purely observational studies (cohort, case-control, cross-sectional), registry-based research, and health-services/outcomes work where no intervention is assigned at all. It is distinct from basic (preclinical, bench-level) research, though the two are connected along a translational research spectrum.
21 CFR Part 50 (Protection of Human Subjects)
21 CFR Part 50 is the FDA's own human-subjects protection regulation. It applies to clinical investigations of products that fall under FDA's regulatory jurisdiction under the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act -- drugs, biologics, and medical devices for human use -- regardless of who funds the study. It sets the informed-consent requirements FDA holds sponsors and investigators to (Subpart B), and adds extra safeguards when children are enrolled (Subpart D). A study triggers Part 50 when it is 'regulated by FDA' under sections 505(i) or 520(g) of the FD&C Act (i.e. it supports or could support an IND or IDE, or the drug/device is otherwise subject to FDA jurisdiction) -- not because a federal agency is paying for it. That funding-vs-jurisdiction distinction is what separates Part 50 from 45 CFR 46 (the Common Rule), and many trials involving both a federal funder and an FDA-regulated product must satisfy both simultaneously.
Trial Master File (TMF)
The Trial Master File (TMF) is the complete, organized collection of essential documents that individually and collectively permit evaluation of the conduct of a clinical trial and the quality of the data it produced, as defined by ICH E6(R2) Section 8. A document belongs in the TMF if it is on the ICH E6 essential-documents list (or a sponsor's/site's approved TMF index derived from it) and falls into one of three time-based groupings: documents generated before the clinical phase begins (protocol, investigator's brochure, IRB/IEC approval, signed agreements), documents generated during the conduct of the trial (protocol amendments, monitoring visit reports, informed consent forms, drug/device accountability records, adverse event reports), and documents generated after the trial is completed or terminated (final study report, subject identification code list, audit certificate). A sponsor maintains a central TMF; each investigator site maintains a parallel Investigator Site File (ISF) covering the same essential-document categories at site level. Today the TMF is almost always maintained electronically as an eTMF, commonly organized using the TMF Reference Model's zone/section/artifact taxonomy rather than an ad hoc folder structure.
Active Substance Master File (ASMF)
An EU/EEA regulatory submission format for a single active substance's manufacturing and quality-control data, split into a non-confidential Applicant's Part (submitted as part of a marketing authorisation application or IMPD) and a confidential Restricted Part (submitted directly to the competent authority by the active-substance manufacturer), and referenced by — never substituting for — the medicinal-product submission it supports.
FDA Recognized Consensus Standards
An FDA Recognized Consensus Standard is a voluntary standard developed by a recognized standards development organization (SDO) -- such as ISO, ASTM International, AAMI, IEC, or CLSI -- that FDA has formally reviewed and added to its 'Recognized Consensus Standards: Medical Devices' database. A standard qualifies as an instance of this category only once FDA has completed its own review and listed it (with a recognition number and a stated extent of recognition -- full, partial, or recognized with FDA-identified deviations); merely being a published ISO/ASTM/AAMI standard, or being commonly cited in industry practice, is not sufficient on its own. Recognition lets a device manufacturer submit a Declaration of Conformity (DoC) to that standard in a premarket submission -- attesting the device conforms (in full or with disclosed deviations) and providing a summary of test methods and results -- rather than submitting the full underlying test data for independent FDA review. The legal basis is Section 514 of the Federal Food, Drug, and Cosmetic Act, as amended by the FDA Modernization Act of 1997 (FDAMA), which directed FDA to establish this recognition process specifically to reduce duplicative review burden for both industry and the agency. FDA can also withdraw or limit recognition (for example when a standard is superseded by a newer edition), so the database -- not the standard's existence or prior use -- is the authoritative, current record of what may be cited via a DoC at any given time.
Safety Data Exchange Agreement (SDEA)
A Safety Data Exchange Agreement (SDEA) is a written contract between two or more legally distinct parties who share development, marketing, licensing, distribution, or co-promotion rights to the same medicinal product, defining how each party will exchange safety information -- adverse event and adverse drug reaction reports, product complaints with a safety component, literature findings, and aggregate safety reports -- so that each party can independently meet its own national and regional pharmacovigilance reporting obligations. An agreement qualifies as an SDEA (rather than some other contract) when it specifies, at minimum: which party holds which pharmacovigilance responsibilities (case intake, medical review, causality assessment, expedited and periodic reporting, literature surveillance, signal detection); the format and timelines for exchanging individual case safety reports (ICSRs) and aggregate reports such as PSURs between the parties, typically set tighter than the underlying regulatory deadlines to leave room for each party's own downstream submission; reconciliation procedures to confirm no cases were missed on either side; and named contacts, including each party's Qualified Person Responsible for Pharmacovigilance (QPPV) where EU obligations apply. SDEAs are prepared with reference to ICH E2A/E2B/E2D definitions and reporting standards and, in the EU, to the EMA's Good Pharmacovigilance Practices (GVP) modules; they can be bipartite (two parties) or tripartite (three, e.g. when a contract research organization or specialty distributor is also party to the arrangement).
Independent Ethics Committee (IEC)
An Independent Ethics Committee (IEC) is the international/non-US regulatory term for the independent body that reviews and approves a clinical trial's protocol, informed consent materials, investigator qualifications, and facilities before enrollment begins, and continues to oversee the trial's ethical conduct throughout its life, to protect the rights, safety, and wellbeing of trial participants. It performs the identical core function as a US Institutional Review Board (IRB): both are independent bodies of medical, scientific, and non-scientific members that review research involving human subjects against the same underlying principles in ICH E6 Good Clinical Practice (GCP). The two terms describe the same regulatory role arising from different national and regional legal traditions, not two different sets of responsibilities -- which is why ICH E6(R2) and industry practice almost always write the pairing as a single unit, 'IRB/IEC.'
ICH Q/S/E/M Guideline Categories (Quality, Safety, Efficacy, Multidisciplinary)
The four-letter taxonomy the International Council for Harmonisation (ICH) uses to organize every technical guideline it publishes: Quality (Q) guidelines cover pharmaceutical development, manufacturing, and stability; Safety (S) guidelines cover nonclinical (in vitro and animal) safety testing such as carcinogenicity, genotoxicity, and reprotoxicity studies; Efficacy (E) guidelines cover the design, conduct, safety reporting, and analysis of human clinical trials, including ICH E6 Good Clinical Practice; and Multidisciplinary (M) guidelines cover cross-cutting topics that don't fit uniquely under Q, S, or E, such as the Common Technical Document (CTD) submission format and MedDRA terminology. Each guideline within a category carries a sequential number (e.g. Q1, S1, E1, M1) and, when revised, a parenthetical revision marker (e.g. E6(R2), E6(R3)); a document isn't a true ICH guideline unless it has progressed through the ICH multi-step process to at least Step 4 adoption by the ICH Assembly.
Clinical Trial Data
Clinical trial data is any information generated or recorded during the conduct of a clinical trial that documents what happened to a participant, what was measured, or how the trial was run -- from a clinician's original observation through to the frozen dataset submitted to a regulator. A given piece of information qualifies as clinical trial data if it is (a) collected under the trial's protocol, from an enrolled participant or the trial process itself, and (b) subject to the trial's data-integrity and traceability controls (audit trail, source-to-database verification, applicable regulatory retention rules) rather than being incidental or off-protocol information. It is a category, not a single artifact: it spans source data (the first recording of an observation), the case report form (CRF) data derived from that source, and the coded, cleaned, and locked datasets used for statistical analysis and regulatory submission.
Research Pharmacy (Investigational Drug Service, IDS)
<p>A <strong>research pharmacy</strong> — also called an <strong>Investigational Drug Service (IDS)</strong> — is the specialized pharmacy unit responsible for the receipt, storage, accountability, preparation, dispensing, and (where applicable) return or destruction of investigational products used in clinical trials, operating under the protocol and Good Clinical Practice (GCP) rather than under routine hospital-formulary dispensing rules. A pharmacy operation qualifies as a research pharmacy when it (1) receives and stores investigational product under sponsor- and manufacturer-specified conditions separate from commercial stock, (2) maintains a full chain-of-custody accountability record for every unit from receipt through final disposition, (3) dispenses only against a valid protocol-specific order tied to subject eligibility and randomization assignment, and (4) where the trial is blinded, restricts access to the randomization code to designated unblinded staff who function independently of the study team members assessing outcomes.</p>
Simulation of Clinical Trials
Simulation of clinical trials is the use of computational and statistical models -- built from preclinical, pharmacokinetic/pharmacodynamic (PK/PD), and prior clinical data -- to predict how a proposed trial design will behave before a single participant is enrolled. A model of the drug, the disease, and the trial process is run many times (commonly via Monte Carlo methods) under different design assumptions to forecast outcomes such as statistical power at a given sample size, the probability of correctly selecting a dose, or the operating characteristics of an adaptive design's decision rules. An activity counts as clinical trial simulation when it (1) uses an explicit quantitative model rather than a rule-of-thumb or expert-opinion estimate, (2) is applied prospectively, during design, to a specific trial or program decision -- not retrospectively to explain results already observed, and (3) produces a distribution of possible outcomes across repeated in-silico trials rather than a single point estimate, letting designers see the probability of success under uncertainty rather than one deterministic answer.
FDA Form 356h
FDA Form 356h ("Application to Market a New or Abbreviated New Drug or Biologic for Human Use") is the standardized cover form an applicant files with a New Drug Application (NDA), Abbreviated New Drug Application (ANDA), or Biologics License Application (BLA). It identifies the applicant and product, states the application type and submission type (original, resubmission, or supplement), indexes the enclosed technical sections, and carries the signed certification statements required for FDA to accept the submission for review. It applies only to drug/biologic marketing applications reviewed by CDER or CBER -- it is not used for medical device submissions, which use a separate CDRH cover sheet (Form 3514).
FDA Priority Review
FDA Priority Review is a designation FDA assigns to a marketing application (a New Drug Application, Biologics License Application, or efficacy supplement) for a drug or biologic that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of a serious condition, compared with available therapy. A Priority Review designation sets FDA's internal review-clock goal at 6 months from the filing date for a first review cycle, instead of the 10-month goal that applies to a Standard Review application. It is one of FDA's four expedited programs for serious conditions, alongside Fast Track, Breakthrough Therapy designation, and Accelerated Approval, but unlike the other three it is a review-timeline classification tied to a completed application rather than a designation sponsors typically request earlier in development.
Inducements in Research (Undue Inducement)
An inducement is any payment, benefit, or opportunity a researcher offers to encourage a prospective participant to enroll in or remain in a study. Offering compensation is not itself a problem: the Belmont Report's respect-for-persons and beneficence principles, and their regulatory implementation at 45 CFR 46.116(a)(1) (Common Rule) and 21 CFR 50.20 (FDA), treat reasonable payment for time and burden as compatible with voluntary consent. An inducement becomes an <em>undue inducement</em> when its size or structure is large enough, or contingent enough, to impair a prospective participant's ability to weigh the study's risks and benefits rationally -- functioning as pressure to enroll or stay enrolled rather than as compensation for burden. Under 45 CFR 46.111(b), an IRB must determine that consent will be sought under circumstances that minimize the possibility of coercion or undue influence; review of the payment plan (amount, schedule, and any completion contingency) is the concrete mechanism through which that determination gets made for offers of payment specifically.
Clinical Study Report (CSR)
A Clinical Study Report (CSR) is the comprehensive, standalone document summarizing the design, conduct, and results of a single clinical trial, prepared in the format defined by ICH E3 (Structure and Content of Clinical Study Reports) so that any ICH regulatory authority can evaluate the trial on its own terms. A document qualifies as a CSR, rather than a lesser trial-reporting artifact, when it (a) integrates the full trial narrative -- objectives, methods, efficacy and safety results, and statistical analyses -- into one report keyed to a specific protocol, and (b) is structured to ICH E3's numbered outline (title page; a roughly three-page synopsis; ethics; investigators; introduction; study objectives; investigational plan; study patients; efficacy and safety evaluation; discussion and conclusions; tables, figures, and appendices), whether or not every section header is used verbatim. A CSR is compiled after database lock, once the trial's data are final, and is submitted to regulators as part of a marketing application (e.g., an NDA, BLA, or MAA) rather than published as an independent research output.
Washout Period
In a crossover clinical trial, a washout period is the interval deliberately built between two consecutive treatment periods during which no study intervention is administered, allowing the effects of the treatment given in the prior period to dissipate before the next treatment period begins. Its function is to prevent a carryover effect -- a residual pharmacological, physiological, or symptomatic effect of the earlier treatment contaminating the outcome measurements taken during the following period. A washout period is only meaningful in designs where the same participant receives more than one treatment in sequence (crossover and N-of-1 designs); it has no equivalent in a parallel-group design, where each participant receives only one treatment for the trial's duration. The length of a washout period is a protocol-specified design parameter, not an incidental gap in scheduling: it is set during protocol development, justified in the statistical analysis plan, and reviewed by the IRB/ethics committee as part of the overall trial design.
Clinical Trial Associate (CTA)
A Clinical Trial Associate (CTA) is an entry-level, sponsor- or CRO-side administrative and project-tracking support role for clinical trials. A CTA maintains the Trial Master File (TMF) and site regulatory documents, schedules meetings and site visits, tracks study timelines and action items, and supports the Clinical Research Associate (CRA)/monitor's workload -- without independently conducting site monitoring visits or exercising the CRA's oversight authority over site conduct. Regardless of exact job title, a role counts as CTA-function work when it is administrative/logistical support performed on behalf of the sponsor or CRO team, not independent site oversight (that is the CRA function) and not day-to-day study conduct at the site itself (that is the Clinical Research Coordinator, or CRC, function).
CAP Biorepository Accreditation Program (CAP-BAP)
The CAP Biorepository Accreditation Program (CAP-BAP) is a voluntary, formal accreditation program run by the College of American Pathologists (CAP), established in 2012 as the first accreditation program specifically for biorepositories. A biorepository is accredited when it undergoes and passes an on-site peer-inspection assessment against a defined set of CAP accreditation checklists covering the Biorepository-specific checklist plus the shared Laboratory General, Director Assessment, and All Common checklists, is re-inspected on-site every two years, and completes a self-inspection using the same checklists in the intervening off-year. The checklists address consent and protection of research participants, specimen collection and chain of custody, institutional governance documents such as material transfer agreements, and long-term preservation infrastructure (equipment maintenance, temperature monitoring, backup systems). CAP-BAP draws on guidance from ISBER, the NCI, and the OECD in building its checklists but is itself a distinct, CAP-branded accreditation credential, not a re-badging of either.
ICF (Informed Consent Form)
The specific written document, IRB-approved before use, that restates a study's required disclosure elements (45 CFR 46.116(b)-(c); for FDA-regulated research, 21 CFR 50.25) for a prospective participant to read and sign. Distinct from the informed-consent process itself, which is documented separately under 45 CFR 46.117 / 21 CFR 50.27 and can, in limited cases (e.g. a documentation waiver, or the short-form pathway for non-English speakers), occur without a conventional long-form signed ICF.
Phase 1 Trial
A Phase 1 trial is the first stage of human testing for an investigational drug or biologic under an IND (21 CFR 312.21), where the primary endpoints are safety, tolerability, pharmacokinetics/pharmacodynamics, and dosing rather than efficacy. It typically enrolls a small cohort (roughly 20-80 participants), advances doses through a pre-specified dose-escalation design (commonly 3+3 or rolling six) governed by dose-limiting toxicity (DLT) criteria, and concludes by establishing a maximum tolerated dose (MTD) and/or a recommended Phase 2 dose (RP2D) that later phases carry forward.
ISO 20387 (Biobanking)
ISO 20387:2018, <em>Biotechnology — Biobanking — General requirements for biobanking</em>, is the international standard specifying requirements for the competence, impartiality, and consistent operation of biobanks. It applies to organisations biobanking biological material and associated data from humans, animals, plants, fungi, and microorganisms for research and development, covering the full chain of collection, preparation, preservation, storage, and distribution of biospecimens. Structurally, it draws on the general competence requirements of ISO/IEC 17025 (testing and calibration laboratories) and the quality-management-system requirements of ISO 9001, adapted specifically for biobanking. A biobank meets ISO 20387 when a national accreditation body (for example UKAS in the UK or ANAB in the US, both operating under the same international accreditation framework as ISO/IEC 17025 labs) has formally assessed and accredited its quality management system, sample traceability, and impartiality — not merely when it follows informal best-practice guidance.
Shared Investigator Platform (SIP)
The Shared Investigator Platform (SIP) is an industry-wide technology platform, originally developed by TransCelerate BioPharma and now operated by Cognizant, that lets clinical investigators and site staff maintain a single reusable profile -- credentials, training records, Good Clinical Practice (GCP) certifications, CVs, and facility/equipment information -- and share it across multiple participating sponsors and CROs, instead of re-submitting the same regulatory and qualification documentation separately to every sponsor for every study. A site interaction counts as using SIP, as distinct from a sponsor's own proprietary site portal, when: (1) the site maintains one Facility Profile and individual user profiles through a single central platform account rather than a sponsor-specific login; (2) that profile data -- training certificates, licenses, CVs, financial disclosure and other startup documents -- is entered once and then made visible, on the site's authorization, to any participating sponsor running a study at that site; and (3) study start-up and conduct activities (document exchange, study-specific training assignment, communication) for a given trial route through the shared platform rather than a separate sponsor-built system. TransCelerate's own Shared Investigator Platform Initiative reached completion in 2020 -- TransCelerate states no new deliverables or updates are planned by the organization -- and the platform is now owned and operated by Cognizant; sponsor and CRO adoption is voluntary and platform use for a given study still depends on which sponsor is running it.
FDA Biosimilars (351(k) Pathway)
An FDA biosimilar is a biological product approved under section 351(k) of the Public Health Service Act (42 U.S.C. § 262(k)) — an abbreviated licensure pathway, distinct from the standard 351(a) Biologics License Application (BLA) route, under which a sponsor relies on an existing FDA-licensed reference product rather than generating the full standalone clinical package a 351(a) BLA requires. A product qualifies as a biosimilar only when FDA determines, on the totality of the evidence, that it is <strong>highly similar</strong> to the reference product notwithstanding minor differences in clinically inactive components, and that there are <strong>no clinically meaningful differences</strong> between the two products in terms of safety, purity, and potency. A biosimilar may additionally earn an <strong>interchangeable</strong> designation, a higher bar that permits pharmacy-level substitution for the reference product without the prescriber's intervention, subject to state pharmacy-substitution law.
eCTD (Electronic Common Technical Document)
A regulatory submission qualifies as an eCTD only when its files are organized into the standardized five-module folder hierarchy (Module 1 region-specific administrative/prescribing information, Module 2 CTD summaries, Module 3 quality/CMC, Module 4 nonclinical study reports, Module 5 clinical study reports) AND wrapped in an XML backbone (index.xml) that assigns each file lifecycle-operation metadata (new, append, replace, delete) so a reviewer's system and the sponsor's own submission history can track changes across amendments to the same application. A folder of complete, correctly-labeled PDFs that lacks the XML backbone and Module 1-5 structure is not an eCTD, regardless of content completeness.
FDA Form 3454 (Certification: Financial Interests and Arrangements of Clinical Investigators)
FDA Form 3454 ('Certification: Financial Interests and Arrangements of Clinical Investigators') is the form a marketing-application sponsor submits to FDA to certify -- rather than disclose -- that no clinical investigator (or subinvestigator, and no covered spouse or dependent child) who participated in a covered clinical study has any of the disclosable financial interests or arrangements defined at 21 CFR Part 54. It is used only when the sponsor's inquiry into each investigator's financial interests comes back clean; if any investigator has a reportable interest or arrangement, the sponsor files the counterpart form, FDA Form 3455, disclosing it instead. The form must be dated and signed by the applicant's chief financial officer or other responsible corporate official, and it is submitted with the marketing application it supports (an NDA, ANDA, BLA, or PMA/510(k) as applicable) rather than at the start of the trial.
21 CFR Part 56 (Institutional Review Boards)
21 CFR Part 56 is FDA's own regulation governing Institutional Review Board (IRB) review of clinical investigations that fall under FDA's product-jurisdiction authority — chiefly studies conducted under an Investigational New Drug (IND) application (21 CFR Part 312), an Investigational Device Exemption (IDE) (21 CFR Part 812), or otherwise submitted to FDA in support of a research or marketing permit (21 CFR Part 813). Per 21 CFR 56.103, any such clinical investigation must receive IRB approval before it may begin and must remain subject to continuing IRB review for its duration; FDA may refuse to rely on data from an investigation that lacked this initial and continuing IRB oversight. Part 56's trigger is the product/application jurisdiction of the study, not its funding source — it applies whether or not any federal grant money is involved, which is the structural feature that distinguishes it from the Common Rule (45 CFR 46), whose trigger is federal funding or conduct. A single trial can therefore fall under the Common Rule only, Part 56 only, or both at once (for example, an NIH-funded IND drug trial), in which case both regulatory tracks' IRB-review and informed-consent requirements must independently be satisfied.
Site Initiation Visit (SIV)
A Site Initiation Visit (SIV) is the visit -- conducted on-site or remotely by a sponsor or CRO monitor (typically a Clinical Research Associate) -- that formally activates an investigational site for a specific clinical trial, immediately before enrollment may begin. A visit counts as an SIV, regardless of format, when it verifies that all site-activation prerequisites are simultaneously in place: current IRB/IEC approval of the protocol and informed consent form, completed staff training (protocol-specific and Good Clinical Practice) for every individual on the delegation-of-authority log, a complete regulatory/essential-document binder per ICH E6(R2) Section 8, receipt and accountability procedures for investigational product and study supplies, and a working understanding among site staff of source documentation and data-entry (EDC) procedures. A visit is NOT an SIV if it occurs before the site has been contracted and IRB-approved (that is a site-selection/pre-study visit) or after the site has already begun enrolling participants (that is a routine/interim monitoring visit or a close-out visit).
Electronic Trial Master File (eTMF)
An eTMF is a software system -- standalone or a CTMS module -- used to create, store, version-control, quality-check, and track the real-time completeness of a clinical trial’s Trial Master File (TMF) electronically, structured against a reference taxonomy such as the TMF Reference Model and, for FDA-regulated trials, generally within the scope of 21 CFR Part 11.
FDA FOIA Request
A written request filed under 5 U.S.C. § 552 and FDA's implementing regulation, 21 CFR Part 20, submitted to FDA's Division of Freedom of Information asking the agency to release records it holds but has not proactively published — most commonly the narrative text of a Form FDA-483, the fuller Establishment Inspection Report, warning letters, or IND/NDA/BLA correspondence not already in a public FDA database.
Accelerated Approval
Accelerated Approval is an FDA regulatory pathway that lets the agency approve a drug or biologic for a serious or life-threatening condition on the basis of an effect on a surrogate endpoint, or an intermediate clinical endpoint, that is reasonably likely to predict the product's actual clinical benefit -- rather than waiting for a completed trial to show that benefit directly. It is authorized under 21 CFR Part 314 Subpart H (drugs, 21 CFR 314.500-314.560) and 21 CFR Part 601 Subpart E (biologics, 21 CFR 601.40-601.46). Approval is conditional: the sponsor must conduct a post-approval confirmatory trial to verify the predicted clinical benefit, and, under the Food and Drug Omnibus Reform Act of 2022 (FDORA, part of the Consolidated Appropriations Act, 2023), FDA can now require that confirmatory trial be underway -- not merely committed to -- at the time of approval or shortly after. If the confirmatory trial fails to verify clinical benefit, or other evidence shows the product isn't safe or effective, FDA can withdraw the approval through an expedited withdrawal procedure that FDORA also created.
Prescription Drug User Fee Act (PDUFA)
The Prescription Drug User Fee Act (PDUFA) is the 1992 U.S. federal law authorizing FDA to collect user fees from companies that submit certain human drug and biologic applications for review, or that are named as sponsors of certain approved prescription drug products. In exchange for these fees, FDA commits to specific performance goals -- most visibly, review-time targets such as the 10-month goal for a Standard Review application and the 6-month goal for a Priority Review application -- set out in a negotiated agreement between FDA and industry that Congress reauthorizes roughly every five years. PDUFA is the funding and accountability mechanism underlying FDA's human drug review program; it is distinct from the individual expedited-review pathways (Priority Review, Breakthrough Therapy, Fast Track, Accelerated Approval) that operate within the review process it funds.
ISO 14155 (Clinical Investigation of Medical Devices for Human Subjects — GCP)
ISO 14155:2020, ‘Clinical investigation of medical devices for human subjects — Good clinical practice,’ is the ISO standard defining GCP requirements — protocol design, informed consent, investigator qualification, sponsor monitoring, adverse-event/device-deficiency reporting, and reporting — for clinical investigations of medical devices in human subjects. It is the device-industry counterpart to ICH E6 for drug and biologic trials.
Clinical Trial Agreement (CTA)
A Clinical Trial Agreement (CTA) is the legally binding contract between a study sponsor (or a Contract Research Organization acting for the sponsor) and the institution/site conducting the trial (and, typically, the Principal Investigator as a party or signatory) that sets the business and legal terms under which the trial will be performed at that site. A document qualifies as a CTA -- as distinct from the protocol, the informed consent form (ICF), or a data/material-transfer agreement -- when it governs the commercial and risk-allocation terms of the relationship rather than the scientific conduct of the study itself: per-subject and milestone budget and payment schedule, indemnification and insurance (including coverage for trial-related subject injury), intellectual property ownership (background vs. foreground), publication and disclosure rights, data ownership and confidentiality, regulatory-compliance representations, and termination and record-retention terms. The protocol defines what will be done scientifically; the ICF discloses risks and obtains a subject's voluntary participation; the CTA is the separate contract that lets the institution and sponsor actually transact -- get paid, allocate liability, and agree who owns and can publish what comes out of the trial.
IND Annual Report
A comprehensive, once-a-year progress summary that a sponsor holding an active Investigational New Drug (IND) application must submit to FDA under 21 CFR 312.33, due within 60 days of the anniversary date the IND went into effect. It covers every study conducted under the IND during the preceding year (status, enrollment, and completion), a summary of IND Safety Reports and subject deaths/dropouts, preclinical findings, manufacturing or microbiological changes, any Investigator's Brochure revisions, Phase 1 protocol modifications, the sponsor's investigational plan for the coming year, and foreign marketing developments. It continues annually for as long as the IND remains active, independent of whether any individual study is enrolling.
21 CFR 312.60 (General Responsibilities of Investigators)
21 CFR 312.60 is the FDA regulation establishing that an investigator conducting an IND-regulated clinical investigation is responsible for: conducting the study according to the signed investigator statement (Form FDA-1572) and the investigational plan/protocol; protecting the rights, safety, and welfare of subjects under the investigator's care; and controlling drugs under investigation, including obtaining informed consent under 21 CFR Part 50 and complying with IRB requirements under 21 CFR Part 56.
TMF Reference Model
The TMF Reference Model is a harmonized, industry-developed taxonomy for organizing Trial Master File (TMF) content into a predictable three-tier hierarchy of Zones, Sections, and Artifacts (with a fourth, more granular Sub-Artifact tier), each artifact carrying a unique ID, a written purpose/definition, and expected trial-phase metadata. A TMF or eTMF is properly described as 'built on' or 'mapped to' the TMF Reference Model when its filing structure and document types trace back to this defined Zone/Section/Artifact scheme rather than an organization's own bespoke folder taxonomy -- it is a classification standard layered on top of the general TMF/eTMF concept, not a synonym for it.
21 CFR Part 314 (Applications for FDA Approval to Market a New Drug)
21 CFR Part 314, "Applications for FDA Approval to Market a New Drug," is the FDA regulation establishing the entire New Drug Application (NDA) and Abbreviated New Drug Application (ANDA) framework: the content and format an application must have (Subpart B, chiefly 314.50), the abbreviated pathway for generics relying on bioequivalence to an already-approved drug (Subpart C), FDA's review process including the filing decision, approval standard, and Complete Response Letter mechanism (Subpart D, 314.101/314.105/314.110), administrative hearing procedures (Subpart E), confidentiality provisions (Subpart G), accelerated approval based on a surrogate endpoint (Subpart H), and approval without human efficacy studies when unethical or infeasible, the "Animal Rule" (Subpart I). It governs a drug from the point a sponsor seeks marketing approval onward, picking up where 21 CFR Part 312 (Investigational New Drug) leaves off at the end of clinical investigation. Two individual Part 314 sections have their own dedicated CASRAI entries: 314.70 (post-approval changes) and 314.80 (postmarketing adverse event reporting), both within Subpart B.
Delegation of Authority (DoA) Log
<p>A <strong>Delegation of Authority (DoA) Log</strong> is the site-level record, maintained for each clinical trial at each investigator site, that documents which specific trial-related tasks the Principal Investigator (PI) has authorized named study-team members to perform, together with each person's qualifications, their signature or initials, and the exact date range during which that authorization was in effect. It answers one question for anyone reviewing the trial afterward — a monitor, an auditor, or an FDA inspector: was the person who performed this specific task actually authorized to perform it, on the date they performed it? A document set qualifies as a compliant DoA log when it names every individual (co-investigator, sub-investigator, clinical research coordinator, research nurse, research pharmacist, or other delegated staff) who performed a trial-related procedure or made a trial-related judgment; lists the specific tasks delegated to that person, not a generic job title; is signed or initialed by both the delegate and the PI; states the start date (and end date, once applicable) of each delegation; and is kept current as staff join, leave, or take on new responsibilities throughout the trial. Under ICH E6(R2) Section 4.1.5, the investigator must maintain a list of appropriately qualified persons to whom significant trial-related duties have been delegated; the DoA log is the standard operational instrument sites use to satisfy that requirement and to demonstrate it during inspection.</p>
Investigator Site File (ISF)
A document or record belongs in an Investigator Site File (ISF) if it demonstrates something only the trial site itself can attest to under ICH E6(R2)'s essential-documents framework -- delegation of authority, site-specific IRB/IEC oversight, staff qualifications, signed informed consent, and site-level investigational-product accountability -- created and maintained by the site itself (not the sponsor or CRO) throughout the trial and kept available for monitoring and inspection.
Site Management Organization (SMO)
A <strong>Site Management Organization (SMO)</strong> is a company that provides staff, infrastructure, and administrative support directly to clinical trial sites -- as distinct from a <a href='/dictionary/term/contract-research-organization-cro'>Contract Research Organization (CRO)</a>, which contracts with the sponsor to manage a trial across multiple sites. An SMO's contractual relationship typically runs to the investigator or site, not the sponsor: it supplies clinical research coordinators (CRCs), regulatory-documentation support, patient-recruitment assistance, and study start-up help to one or more physical sites, and in many cases owns or directly operates a network of sites itself. Unlike the CRO, which is explicitly defined in <a href='/dictionary/term/ich-e6r2'>ICH E6(R2)</a> Section 5.2 and (for FDA-regulated drug trials) 21 CFR 312.52, an SMO has no equivalent formal regulatory definition -- it is an industry business-model term, not a regulatory delegation category.
Clinical Operations
Clinical operations (often shortened to "clin ops") is the organizational function responsible for the logistical and operational execution of a clinical trial once it has been designed and funded: selecting and activating sites, staffing and managing the monitoring function, overseeing clinical data management systems, coordinating investigational-product supply, managing third-party vendors (labs, imaging cores, IRT/RTSM providers), and tracking trial progress against timeline and budget. A function is properly described as clinical operations when its output is the trial actually running -- sites open, participants enrolled, data flowing, product supplied -- rather than deciding what the trial should study (clinical development) or generating the wider evidence base a study contributes to (clinical research).
ICH Q10 (Pharmaceutical Quality System)
ICH Q10 (Pharmaceutical Quality System) is the ICH Quality-series guideline that defines a model pharmaceutical quality system (PQS) spanning a product's entire life cycle -- pharmaceutical development, technology transfer, commercial manufacturing, and product discontinuation. A quality system meets ICH Q10 when it (1) sits on top of applicable Good Manufacturing Practice (GMP/ICH Q7) requirements and incorporates ISO 9001 quality-management-system principles, (2) applies the risk-based tools of ICH Q9 (Quality Risk Management) to prioritize and scope quality decisions, (3) uses the science- and risk-based product/process understanding built during development under ICH Q8 (Pharmaceutical Development), and (4) operates four specific management enablers -- a Process Performance and Product Quality Monitoring System, a Corrective and Preventive Action (CAPA) system, a Change Management System, and Management Review -- under documented senior-management responsibility and a stated commitment to continual improvement.
Declaration of Helsinki
The Declaration of Helsinki is the World Medical Association's statement of ethical principles for medical research involving human participants, first adopted in 1964 (Helsinki) and revised at WMA General Assemblies through the most recent revision, adopted October 19, 2024. It is the operative ethical reference a physician-investigator, sponsor, or ethics committee cites specifically for physician-conducted medical research -- distinct from the Nuremberg Code (a fixed 1947 tribunal judgment) and the Belmont Report (a US-specific 1979 national-commission document underlying the Common Rule) -- and it is the ethical source ICH E6 Good Clinical Practice cites as the origin of its own principles. A study or protocol is judged against the Declaration when the question is whether independent ethics-committee review occurred, informed consent was genuinely obtained, any placebo/no-treatment control arm was ethically justified, and results-transparency obligations were met.
Source Documentation (Source Documents / Source Data)
Source documentation is the body of original records -- medical charts, laboratory reports, imaging studies, pharmacy dispensing logs, subject diaries, correspondence, and automated instrument printouts -- in which clinical findings, observations, or other trial-related activities are first captured, at the point and time they occur. The information those records contain is source data; the records themselves are source documents. A record only counts as a source document for a given data point if it is where that data point was originally recorded -- a transcription onto a separate worksheet or data-collection tool is not itself a source document unless no earlier original record exists. Per ICH E6(R2) Section 1.51, source data is 'all information in original records and certified copies of original records of clinical findings, observations, or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial'; Section 1.52 defines source documents as the original documents, data, and records containing that information. To be inspection-ready and support reconstruction of the trial, source documentation must satisfy the ALCOA-C principles: Attributable (identifies who recorded it and when), Legible, Contemporaneous (recorded at the time of the observation, not backfilled), Original (the first record, or a verified certified copy), Accurate, and Complete.
CAPA (Corrective and Preventive Action)
CAPA (Corrective and Preventive Action) is the formal quality-system process an organization uses to investigate a finding -- an audit observation, a protocol deviation, an FDA Form 483 observation, or any other nonconformity -- determine its root cause, implement a correction and corrective action to eliminate that cause, take preventive action to stop the same or a similar problem recurring elsewhere in the system, and verify afterward that those actions actually worked.
ANZCTR (Australian New Zealand Clinical Trials Registry)
The Australian New Zealand Clinical Trials Registry (ANZCTR) is the primary online registry for clinical trials conducted in Australia and New Zealand, distinguished from clinical trial registration generally by being the specific bi-national system, housed and managed by the NHMRC Clinical Trials Centre at the University of Sydney since 2005, that assigns every registered study a unique ACTRN (Australian Clinical Trial Registration Number) and was, in 2007, one of the first three registries the World Health Organization recognized as a Primary Registry under its International Clinical Trials Registry Platform (WHO ICTRP).
Medical Device Amendments of 1976
The Medical Device Amendments of 1976 (Pub. L. 94-295) is the U.S. federal statute, signed by President Gerald Ford on May 28, 1976, that amended the Federal Food, Drug, and Cosmetic Act (FD&C Act) to create the modern medical device regulatory framework. Before 1976, FDA had essentially no premarket authority over devices -- only the FD&C Act's general adulteration and misbranding provisions applied, the same standard used for drugs since 1938 but poorly suited to the mechanical, electrical, and implantable nature of devices. The Amendments added Section 513 to the FD&C Act, establishing a risk-based, three-tier classification system (Class I, II, III) and, for the first time, two premarket regulatory pathways keyed to that classification: premarket notification (what the statute's own section number gave us as the now-familiar '510(k)') and premarket approval (PMA) for the highest-risk devices. Devices already legally on the U.S. market when the law took effect were not retroactively required to prove safety and effectiveness from scratch; they were classified based on their existing marketing history, and later devices could establish 510(k) eligibility by claiming 'substantial equivalence' to one of these pre-1976 devices or to a device subsequently cleared through that same route -- the origin of the 'predicate device' concept that still anchors the 510(k) pathway today.
IND Exemption (21 CFR 312.2(b))
The regulatory determination, made by a sponsor under 21 CFR 312.2(b), that a clinical investigation of a drug already lawfully marketed in the United States does not require an Investigational New Drug (IND) application because the study meets all five conditions in the rule: it is not intended to support a new indication or a significant labeling/advertising change, it does not significantly increase the risk (or decrease the acceptability of risk) associated with the drug's approved use, it is conducted in compliance with IRB review (21 CFR Part 56) and informed consent (21 CFR Part 50) requirements, it is not intended to promote the drug for an unapproved use, and it does not involve a route of administration, dosage level, patient population, or other factor that significantly increases the risks associated with the drug's approved use. All conditions must be met simultaneously; failing any one of them means the study needs a full IND regardless of how the others resolve.
21 CFR 314.70 (Changes to an Approved NDA or ANDA)
21 CFR 314.70 is the FDA regulation ("Supplements and other changes to an approved NDA," applied to ANDAs via 21 CFR 314.97) that requires the holder of an approved New Drug Application or Abbreviated New Drug Application to classify every post-approval change to the product, its manufacturing, or its labeling into one of four reporting tracks based on the change’s potential to adversely affect identity, strength, quality, purity, or potency: a Prior Approval Supplement (PAS) for major changes, requiring FDA approval before distribution of product made using the change; a Changes Being Effected in 30 Days supplement (CBE-30) for moderate-risk changes, permitting distribution 30 days after FDA receives the supplement absent an FDA objection; a Changes Being Effected in 0 Days supplement (CBE-0) for a narrower, FDA-designated set of lower-risk changes (most notably certain safety labeling updates), permitting distribution immediately upon FDA’s receipt; and the Annual Report track for minor changes, which are simply documented in the applicant’s next annual report rather than submitted as a standalone supplement. The applicable category is determined by the nature of the specific change, not by applicant discretion.
ePRO (Electronic Patient-Reported Outcomes)
ePRO is the electronic capture of a Patient-Reported Outcome (PRO) directly from a clinical trial participant -- via a provisioned or patient-owned (BYOD) device, app, wearable, or web portal -- without amendment or interpretation by site staff. A data point qualifies as ePRO only when three conditions hold together: (1) the underlying instrument is a validated PRO measure with a defined concept of interest and context of use; (2) the response is entered by the patient at the point of report, not transcribed later by a coordinator or clinician; and (3) the capture system produces a timestamped, attributable, auditable electronic record sufficient to serve as source data for FDA inspection. It is distinguished from Clinician-Reported Outcome (ClinRO) data entered into the trial's eCRF by a site investigator, and from a paper PRO diary that a coordinator later keys into an EDC system -- both of those break the direct-from-patient chain that defines a PRO in the first place.
Medical Device Reporting (MDR)
Medical Device Reporting (MDR) is FDA's mandatory adverse-event reporting system under 21 CFR Part 803, requiring device manufacturers, importers, and device user facilities (hospitals, nursing homes, outpatient facilities) to notify FDA when they become aware that a device may have caused or contributed to a death or serious injury, or has malfunctioned in a way that would likely cause death or serious injury if the malfunction recurred. It is distinct from the EU's 'MDR' (Regulation (EU) 2017/745, the Medical Device Regulation governing premarket CE marking and market access) -- the two share only an acronym, not a regulatory function.
IND Safety Report
A written or electronic notification that a sponsor holding an active Investigational New Drug (IND) application must submit to FDA, and to every participating investigator, under 21 CFR 312.32, whenever the sponsor determines there is reasonable possibility that the investigational drug caused a serious and unexpected adverse event (i.e., the event qualifies as a suspected unexpected serious adverse reaction, or SUSAR). It is distinct from routine investigator-to-sponsor adverse event reporting, from the IND annual report, and from post-marketing adverse-event reporting under 21 CFR 314.80, which applies only after a drug is approved.
Standard Operating Procedure (SOP)
In a research context, a Standard Operating Procedure (SOP) is a written, controlled, step-by-step instruction for performing a specific recurring task the same way every time it is performed, regardless of who performs it -- distinct from a protocol, which specifies what a particular study will do, and from a policy, which states an institution's general position or requirement. A document counts as a research SOP only if it is: (1) task- or process-specific rather than study-specific (e.g. "how this laboratory calibrates a balance" or "how this site receives and stores investigational product," not "what Study ABC-123 will test"); (2) formally approved and version-controlled, with an identifiable author, approver, effective date, and version/revision history; (3) written in enough procedural detail that a trained staff member unfamiliar with that specific instance of the task could follow it and produce a consistent, auditable result; and (4) actually followed and enforced in practice, with deviations documented -- an unused or unenforced document is not functioning as an SOP even if it is labeled one.
Pragmatic Trial
A pragmatic (clinical) trial is a randomized controlled trial designed to measure an intervention's effectiveness under conditions that resemble routine, real-world care, rather than its efficacy under tightly controlled, ideal conditions. It is still an experimental, randomized design -- what distinguishes it from an explanatory trial is a cluster of protocol choices: broad eligibility criteria that mirror the population who would actually receive the intervention, delivery in usual-care settings by usual-care staff, flexible (rather than rigidly standardized) treatment protocols, a usual-care or standard-of-care comparator instead of placebo, and outcomes that matter to patients and decision-makers (e.g., hospitalization, function, quality of life) rather than surrogate or mechanistic endpoints. No trial is purely pragmatic or purely explanatory; every trial sits somewhere on a continuum between the two, and the PRECIS-2 (PRagmatic-Explanatory Continuum Indicator Summary-2) tool is the standard instrument for locating a given trial's design on that continuum, domain by domain, rather than as a single binary label.
Condition Code 30
Condition Code 30 is the two-digit value ("30 – Qualifying Clinical Trial") entered in the condition codes field of an institutional Medicare claim (UB-04 / CMS-1450, or the equivalent field on the electronic 837I transaction) to flag that the claim includes items or services furnished in connection with a qualifying clinical trial under Medicare's Clinical Trial Policy (National Coverage Determination 310.1). A claim requires Condition Code 30 when the trial meets NCD 310.1's qualifying criteria (falls within a Medicare benefit category, has therapeutic intent, and satisfies one of the NCD's deeming criteria — including NIH, FDA IND, or VA/DOD/CDC/AHRQ/CMS-funded/-supported studies) and the provider is billing Medicare for routine patient-care costs alongside the trial. It is reported on ALL clinical-trial-related institutional claims from a qualifying study, whether or not every line item on that particular claim is trial-related, and is submitted together with ICD-10 diagnosis code Z00.6 (encounter for examination for normal comparison and control in clinical research) and the trial's eight-digit National Clinical Trial (NCT) number — reported as UB-04 value code D4, or in loop 2300, REF02 (REF01 = P4) on the 837I. It functions purely as a claims-processing flag: it does not itself create coverage, it tells the Medicare Administrative Contractor (MAC) which coverage rules to apply to the claim.
Central IRB / Single IRB (sIRB)
The model in which one IRB of record -- rather than each participating site's local IRB -- conducts the ethical review for a multi-site human-subjects study under a single approved protocol, with all other participating sites relying on that review through a documented reliance arrangement (typically an IRB Authorization Agreement) instead of each convening a duplicate local review.
NIDA GCP Training
NIDA GCP Training refers to the Good Clinical Practice training course developed and administered by NIDA's Center for the Clinical Trials Network (CCTN), the coordinating body for the National Institute on Drug Abuse's Clinical Trials Network (CTN) -- a network of research sites and community treatment programs that conducts multisite trials on substance use disorder treatments. The course is not a separate regulatory standard: its content is built on the same underlying framework as ICH E6 Good Clinical Practice and applicable U.S. Code of Federal Regulations (CFR) provisions for human subjects research, but it is packaged, delivered, and administered specifically by NIDA/CCTN rather than by a third-party provider such as the CITI Program. A record is a genuine instance of 'NIDA GCP Training' when the completion certificate was issued through NIDA's own training platform (gcp.nidatraining.org) rather than through a different GCP course that merely also references ICH GCP.
Protocol Amendment
A protocol amendment is a written, sponsor-initiated description of a change to, or formal clarification of, an already IRB/IEC-approved research protocol. Under ICH E6(R2) Section 1.60, that is the formal definition. An amendment is planned and prospective: it must be submitted to and reviewed by the IRB/IEC (and, for FDA-regulated drug trials, separately reported to FDA under 21 CFR 312.30) and receive documented approval before the changed procedures take effect, with two narrow exceptions -- a change made to eliminate an immediate hazard to subjects, and a change that is purely logistical or administrative (e.g., a monitor's phone number) and does not affect subject safety, rights, welfare, or the scientific integrity of the study. This prospective-approval requirement is what separates an amendment from a <a href='/dictionary/term/protocol-deviation'>protocol deviation</a>, which is an unplanned departure discovered and documented after the fact.
FDA Form 3926
FDA Form 3926, officially the "Individual Patient Expanded Access Investigational New Drug Application," is the streamlined form a treating physician uses to request FDA authorization for a single named patient to receive an investigational drug -- or an approved drug whose availability is restricted by a Risk Evaluation and Mitigation Strategy (REMS) -- outside a clinical trial, under the individual-patient category of FDA's expanded access ("compassionate use") pathway codified at 21 CFR Part 312, Subpart I. A request counts as a Form 3926 submission when: (1) the treating physician (not the manufacturer) files it with the relevant FDA review division, or in a genuine emergency initiates the request by phone/other rapid means and completes the form afterward; (2) the manufacturer/sponsor has agreed, generally via a Letter of Authorization, to supply the product for this specific patient; (3) the physician has documented the patient's brief clinical history, prior therapy, and treatment plan (dose, route, schedule, duration, monitoring) in the form's required sections; and (4) FDA has not objected within the applicable waiting period. Form 3926 is FDA's purpose-built, physician-oriented alternative to filing a full commercial IND application on Form FDA 1571 -- it is not used for multi-patient or sponsor-initiated expanded access categories, and it is not part of the separate Right to Try Act pathway.
RTSM (Randomization and Trial Supply Management)
A system counts as RTSM (Randomization and Trial Supply Management) -- also called IRT (Interactive Response Technology) -- if, within a single platform used by trial sites, it performs at least one of: (1) subject randomization to a treatment arm per the protocol's randomization scheme at enrollment, with blind maintenance and an auditable emergency-unblinding path where the trial is blinded; or (2) trial-supply management -- real-time kit- or dose-level inventory tracking and automatic resupply triggering to sites or depots. Most production RTSM/IRT platforms do both together. A platform that only captures clinical data (an EDC) or only manages site financial, regulatory, and monitoring workflow (a CTMS) is not RTSM/IRT, even though all three are routinely used side by side, and sometimes integrated, on the same trial.
Clinical Data Abstraction
Clinical data abstraction is the process by which a trained abstractor reads unstructured or semi-structured source documents — electronic health record (EHR) notes, paper charts, radiology reports, pathology reports, discharge summaries, operative notes — and extracts, interprets, and re-enters the relevant data points into a structured study database according to a written abstraction protocol and predefined data dictionary. It is distinguished from prospective data entry in two ways: the source material is not a study-specific form filled out by the person generating the data, and abstraction always involves a human judgment step (locating the relevant fact inside free text and mapping it to the correct structured field) rather than transcription of an already-structured value. A process counts as clinical data abstraction, as opposed to routine data entry, when all of the following hold: (1) the source document was created for clinical care or another non-research purpose, not for the study itself; (2) an abstractor applies a documented protocol and coding conventions to decide what counts as a positive/negative finding, which date or value to use when a chart contains conflicting entries, and how to handle missing or ambiguous information; and (3) the resulting structured value is auditable back to a specific location in the source document (a practice generally called source traceability or query-back-to-source).
ICH Q9 (Quality Risk Management)
ICH Q9 (Quality Risk Management) is the ICH guideline establishing a systematic process — risk assessment, risk control, risk communication, and risk review — for evaluating, controlling, and communicating risks to pharmaceutical quality across a product's lifecycle. A quality decision follows ICH Q9 when it (1) is grounded in scientific and clinical knowledge ultimately linked to patient protection, (2) applies effort and documentation proportionate to the level of risk involved, and (3) uses a structured method — such as FMEA, FMECA, or HACCP — rather than an ad hoc or purely subjective judgment.
Crossover Study Design
A crossover study is a trial design in which each participant receives two or more of the interventions under comparison in a randomized sequence, separated by a washout period, so that within-participant outcomes on each intervention can be directly compared. It differs from a parallel-group design (one arm per participant, between-group comparison) and from an N-of-1 trial (identical within-subject logic applied to a single patient rather than a cohort, for an individual rather than a population-level conclusion).
Protocol Deviation
A protocol deviation is any unplanned departure -- by the investigator, study staff, or a subject -- from the procedures, visit schedule, eligibility criteria, or other requirements set out in the IRB/IEC-approved clinical trial protocol, made without prior sponsor agreement and prior IRB/IEC approval. It is distinct from a protocol amendment, which is a formal, prospectively reviewed and approved change to the protocol itself. Deviations are typically classified by severity -- commonly as minor/administrative versus important (also called major or significant) -- based on whether they affect subject rights, safety, or well-being, or the completeness, accuracy, or reliability of study data.
Chemistry, Manufacturing, and Controls (CMC)
A regulatory submission qualifies as containing CMC information when it documents, for a specific drug substance and/or drug product, the identity, composition, and manufacturing process used to produce it; the in-process controls and specifications (analytical test methods and acceptance criteria) used to confirm its strength, quality, and purity at each stage; and the stability data supporting the proposed container closure system and shelf life. In an eCTD-formatted submission to FDA or another ICH-aligned regulator, this material is filed as Module 3 (Quality) -- CMC is the informal, universally-used shorthand for that module's content, not a separate submission or a formal ICH-defined term itself. A document that describes only the clinical protocol, nonclinical toxicology, or regulatory administrative forms, with no data on how the product is made, tested, or controlled, does not constitute CMC information regardless of how complete it is on those other dimensions.
EU Clinical Trials Regulation (CTR) & CTIS
A clinical trial is governed by the EU Clinical Trials Regulation (Regulation (EU) No 536/2014, the "CTR") -- and therefore must be authorised and registered through the EU's Clinical Trials Information System (CTIS) -- when it (1) is an interventional trial (not a purely observational/non-interventional study), (2) tests a medicinal product for human use (not a medical device, which falls under the MDR/IVDR instead), and (3) includes at least one trial site in an EU/EEA member state. Since CTIS became the sole authorisation and registration route on 31 January 2025 -- completing a three-year transition away from the prior Clinical Trials Directive 2001/20/EC and the EudraCT/EU Clinical Trials Register it used -- this applies whether the trial runs in a single member state or spans multiple countries via one application, one Reporting Member State (RMS), and any number of other Member States Concerned (MSC).
Conflict of Interest in Human Subjects Research
A conflict of interest in human subjects research exists when an investigator's, institution's, or IRB member's financial or personal interest could compromise -- or reasonably appear to compromise -- the design, conduct, oversight, or reporting of a study involving human participants. Unlike the general research-COI concept, review here is tied directly to the IRB approval decision: federal guidance and institutional policy require that a significant financial conflict be evaluated and, where warranted, managed under a documented plan before the IRB may approve the protocol, and require any IRB member with a conflicting interest in a specific protocol to recuse from reviewing or voting on it.
21 CFR Part 54 (Financial Disclosure by Clinical Investigators)
21 CFR Part 54 is the FDA regulation requiring sponsors of a covered clinical study to obtain, and FDA to evaluate, information about certain financial interests and arrangements held by the clinical investigators who conducted the study. It applies to any 'covered clinical study' -- a study in humans that a marketing applicant or FDA relies on to establish a product's effectiveness (including a study demonstrating equivalence to an approved product), or a study in which a single investigator's data makes a significant contribution to the demonstration of safety -- submitted in support of an NDA, ANDA, BLA, or a device marketing application (PMA or certain 510(k)s). Rather than banning financially interested investigators from participating, Part 54 requires the sponsor to certify (via FDA Form 3454) that no covered investigator has a disclosable financial interest, or to disclose (via FDA Form 3455) any that exist, so FDA can factor that information into its evaluation of the study's reliability. Sections 54.5 and 54.6 -- FDA's authority to act on disclosed interests and the sponsor's recordkeeping obligation -- are part of Part 54 itself but are not addressed by either form.
FDA Form 3455 (Disclosure: Financial Interests and Arrangements of Clinical Investigators)
FDA Form 3455 ('Disclosure: Financial Interests and Arrangements of Clinical Investigators') is the form a marketing-application sponsor files with FDA when its financial-interest review, conducted under 21 CFR Part 54, finds that one or more clinical investigators (or a subinvestigator, spouse, or dependent child) participating in a covered clinical study has a disclosable financial interest or arrangement -- e.g. compensation tied to study outcome, equity in the sponsor exceeding the regulatory thresholds, a proprietary interest in the tested product, or significant payments beyond direct study costs. Rather than certifying the interests' absence (the role of the counterpart form, FDA Form 3454), Form 3455 requires the sponsor to disclose the interest completely and accurately -- its nature and, where applicable, its value -- and, per 21 CFR 54.4(a)(3), describe what steps, if any, were taken to minimize its potential to bias the study's design, conduct, or reporting. It is submitted with the marketing application the covered study supports.
Low- and Middle-Income Countries (LMIC)
LMIC is a World Bank income-classification category, combining the low-income, lower-middle-income, and upper-middle-income groups, used as a proxy for national economic development level. The World Bank sorts every economy into one of four groups (low-income, lower-middle-income, upper-middle-income, high-income) once a year, effective every 1 July, based on Gross National Income (GNI) per capita for the prior calendar year, converted to US dollars using the Atlas method. 'LMIC' is shorthand for the three non-high-income groups combined. In research administration, LMIC status determines eligibility for a large number of funder schemes, informs risk and vulnerability considerations in ethics review, and is used as a proxy variable in equity-in-research-participation and authorship analyses. A country's classification can and does change from year to year as its GNI per capita moves relative to the thresholds, so an eligibility list or dataset citing 'LMIC' status should always specify the fiscal year it draws on.
Clinical Equipoise
Clinical equipoise is the state of genuine uncertainty, held within the expert medical community as a whole (not necessarily by any one investigator), about the comparative therapeutic merit of a randomized controlled trial's arms. It is the ethical precondition that justifies randomizing participants to a control or comparator arm rather than assigning known-superior treatment to everyone; it is disturbed, and randomization becomes unethical, once credible evidence resolves that community-wide uncertainty toward one arm.
Electronic Batch Record (EBR)
An Electronic Batch Record (EBR) is the electronic-system equivalent of a paper batch record in GMP-regulated manufacturing: the record documenting, for one specific manufactured batch, that each step of the validated Master Production Record was performed -- by whom or by which qualified automated equipment, when, with what materials and quantities, and with what in-process results -- retained in a system meeting 21 CFR Part 11 controls (validation, independent audit trail, access control, attributable electronic signatures) because it is the electronic record being used to satisfy the GMP predicate requirement at 21 CFR 211.188. A record only functions as an EBR, rather than a digitized image of a paper record, if the generating system itself is validated and Part-11-compliant.
Real-World Evidence (RWE)
Real-World Evidence (RWE) is clinical evidence about the usage, benefits, or risks of a medical product derived from the analysis of Real-World Data (RWD) -- data relating to patient health status and/or care delivery that is routinely collected outside the controlled setting of a randomized controlled trial (RCT). RWD sources include electronic health records (EHRs), medical claims and billing data, product and disease registries, and data from digital health technologies or patient-generated sources. RWE becomes regulatory-grade evidence only after the underlying RWD has been assessed as fit for use -- relevant, reliable, and sufficiently complete for the specific question being asked -- and the study design (e.g., pragmatic trial, prospective registry study, or retrospective database analysis) adequately addresses confounding and bias, since RWE studies typically lack the randomization and blinding that isolate causal effect in a traditional RCT.
Medical Research Future Fund (MRFF)
The Medical Research Future Fund (MRFF) is the Australian Government's dedicated long-term financing vehicle for health and medical research and innovation, established under the Medical Research Future Fund Act 2015. A grant is an MRFF grant when its funding is drawn from the investment earnings of the MRFF's invested capital (rather than from annual Budget appropriations, as with most NHMRC National Competitive Grants Program funding) and is disbursed against a specific MRFF grant opportunity listed on GrantConnect, typically under one of the MRFF's Research Missions or the broader MRFF Strategy and Priorities set by the Australian Medical Research Advisory Board (AMRAB) — even where the grant opportunity is administered day-to-day by NHMRC, a Business Grants Hub, or another delegated body on the Department of Health, Disability and Ageing's behalf.
Human Research Participant (Human Subject)
A human research participant (the regulatory term is "human subject") is a living individual about whom an investigator conducting research either obtains information or biospecimens through intervention or interaction, or obtains, uses, studies, analyzes, or generates identifiable private information or identifiable biospecimens (45 CFR 46.102(e)). "Subject" is the term used in the Common Rule and IRB paperwork; "participant" is the term preferred by APA style and many journals for manuscript prose. Both refer to the same regulatory category of person.
Non-Interventional Study
A non-interventional study is a clinical study of a medicinal product in which treatment assignment is not decided in advance by a protocol, prescribing and enrollment decisions are kept separate, and no diagnostic or monitoring procedures beyond normal clinical practice are imposed. Under EU Regulation (EU) No 536/2014, Article 2(2)(4), it is defined directly as any clinical study that is not a clinical trial. The classification determines whether a study needs prior competent-authority/ethics approval under the EU Clinical Trials Regulation, whether it triggers an FDA IND, and which registration/reporting regime applies.
Community Advisory Board (CAB)
A Community Advisory Board (CAB) is a standing group of community members, patient/participant representatives, and other local stakeholders that provides ongoing, non-scientific input into the design, conduct, and dissemination of a research study or program from the perspective of the population it affects. A body qualifies as a CAB when it (1) is composed primarily of community members or affected-population representatives rather than research staff or clinicians, (2) advises on matters such as protocol acceptability, recruitment and retention strategies, informed-consent language, culturally appropriate messaging, and dissemination of results, and (3) operates on an advisory, non-binding basis — it does not have authority to approve, halt, or scientifically review the study. This distinguishes a CAB from bodies with formal regulatory or scientific-oversight authority, such as an Institutional Review Board (IRB), which reviews and approves research for ethical and regulatory compliance, or a Data Safety Monitoring Board (DSMB), which reviews accumulating safety and efficacy data during a trial. A CAB's role is community voice and engagement, not protocol approval or safety monitoring.
